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Abstract  
Background 
Psoriasis is now recognised as a systemic disease centered on inflammation and 
involvement of cytokines of the Th1 pathway. There are recent studies showing higher 
prevalence of vitamin D deficiency in patients with psoriasis than in control groups.(10–13) The 
discovery of the systemic role of vitamin D in the modulation of the immune system especially 
the Type 1 helper T cell (Th1) pathway suggests that low levels of vitamin D may have 
important implications in the pathogenesis of psoriasis.  
Objectives 
Our primary objective was to determine the 25-hydroxyvitamin D status of patients with 
chronic plaque psoriasis in comparison with age and sex matched controls as a pilot study.  Our 
secondary objective was to correlate the psoriasis disease characteristics with vitamin D level. 
Methods 
 Forty-five consecutive consenting patients with chronic plaque psoriasis and 45 age and sex 
matched controls with minor dermatological diseases from Tamil Nadu were recruited in this 
study. Data on demographic profile, sun-exposure, sunscreen usage, smoking, alcohol, type of 
clothing, waist circumference, vitamin D level, fasting and post prandial sugars, total cholesterol, 
triglycerides, LDL and HDL were collected from all study participants. From the patients with 
psoriasis, data on duration of disease, disease severity as assessed by BSA and PASI, presence of 
arthritis / nail changes were also collected. 
Results 
The overall prevalence of vitamin D deficiency (≤ 20ng/ml) in the study subjects was 
53.33%. Sixty two per cent cases and 44% controls had vitamin D deficiency with the observed 
difference not being statistically significant (p value = 0.096). The mean serum vitamin D level 
was similar among the cases and controls, 21.54 ± 9.41ng/ml and 21.24 ± 10.97 respectively (p = 
0.64). There was no statistically significant difference ( p = 0.15) in the mean vitamin D level 
between patients with type 1 psoriasis (19.56 ±9.8 ng/ml) and  type 2 psoriasis (25.86 ± 12.99 
ng/ml). The mean serum vitamin D level was significantly (p = 0.0001) lower in patients who 
wore covered type of clothing (14.48 ± 6 ng/ml) when compared to those who wore clothing that 
allowed more photo-exposure (23.23 ± 10.28 ng/dl). With an increase in disease duration, there 
was a tendency towards decrease in vitamin D level (r = -0.2978, p = 0.047). There was no 
correlation between vitamin D level and psoriasis disease severity measures like PASI and BSA 
involvement, presence of arthritis and nail changes. The BMI (r = -0.300, p = 0.045) and fasting 
blood sugar (r = -0.319, p = 0.037) showed a negative correlation and the HDL level (r = 0.34, p 
= 0.026) showed a positive correlation with vitamin D level. Logistic regression analysis did not 
show any significant changes in vitamin D level attributable to the presence of psoriasis after 
adjusting for clothing, skin type, locality, occupation, sun exposure and BMI. In addition, the 
pattern of clothing was observed to be strongly associated with changes in vitamin D level after 
adjusting for confounders. 
Key words – vitamin D, psoriasis, metabolic syndrome 
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Introduction 
  
Psoriasis is a chronic debilitating skin disease that affects millions of people 
worldwide.(1) It is characterised by epidermal hyperproliferation and disordered maturation. It 
was once thought to be a disorder of the keratinocyte.(2) But it is now well known that it is a 
disorder involving the innate immunity, acquired immunity and dendritic cells bridging the gap 
between the two.(3) It is recognised as a T cell mediated inflammatory disorder with 
hyperproliferation of epidermal keratinocytes in genetically predisposed individuals.(4) 
Vitamin D has gained attention in the past decade with more and more studies 
demonstrating the varied functions of vitamin D in the body other than its established role in 
bone and mineral metabolism. In the context of psoriasis, it has been used as topical formulations 
(calcipotriol, calcitriol and tacalcitol) for the treatment of psoriasis either as monotherapy or in 
combination with topical steroids.(5)  Vitamin D is now known to influence the immunological 
function of dendritic cells as well as T cells, which are the key players in the pathogenesis of 
psoriasis.(6,7) Through vitamin D receptor (VDR), 1,25-dihydroxyvitamin D3  is shown to 
inhibit the proliferation of cultured human keratinocytes and to induce terminal differentiation of 
these keratinocytes.(8) Certain types of VDR gene polymorphisms have been found to be 
associated with psoriasis.(9) There are recent studies showing increased prevalence of vitamin D 
deficiency in patients with psoriasis when compared to control groups.(10–13) 
 Psoriasis vulgaris is now also known to be associated with metabolic syndrome. 
Metabolic syndrome comprises of obesity, diabetes mellitus, hypertension, low levels of HDL 
and hypertriglyceridemia.(14,15) Studies also show an  association between vitamin D 
deficiency and metabolic syndrome.(16) Psoriasis has been shown to be associated with vitamin 
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D deficiency even after adjusting for confounders including high body mass index in some 
studies.(12) 
There were no published Indian studies on the association between vitamin D and 
psoriasis vulgaris at the commencement of this study. However a recent study done from 
Mumbai, India has shown higher prevalence of vitamin D deficiency among psoriatics as 
compared to controls.(17) This study was designed to study the association between vitamin D 
and psoriasis vulgaris in south Indian population. 
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Aim and Objectives 
  
Aim  
To study the 25-hydroxyvitamin D status of patients with psoriasis vulgaris in a tertiary 
care centre in south India. 
Primary Objective  
To determine the 25-hydroxyvitamin D status of patients with chronic plaque psoriasis in 
comparison with age and sex matched controls with non-psoriatic, non-photosensitive skin 
diseases presenting to the outpatient department (OPD) as a pilot study. 
Secondary Objective  
To correlate the psoriasis disease characteristics with vitamin D level 
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 Review of literature 
 
Psoriasis is a chronic inflammatory and hyperproliferative skin disorder which is now 
recognised as a systemic disease. Clinical lesions result from hyperproliferation and abnormality 
in the differentiation of keratinocytes and epidermal infiltration with inflammatory cells.(18) The 
pathogenesis of psoriasis is centered on inflammation with involvement of cytokines belonging 
to Type 1 helper (Th1) pathway. Vitamin D acts on the vitamin D receptor (VDR) to regulate 
keratinocyte growth and differentiation. The discovery of the role of vitamin D in the modulation 
of the immune system especially the Th1 pathway suggests that low levels of vitamin D may 
have important implications in the pathogenesis of psoriasis.(19)  
Vitamin D  
Vitamin D has gained attention in the past decade with several recent reports showing its 
varied role apart from the well-established role in bone and mineral metabolism. It is now 
regarded as a hormone rather than a vitamin. The skin is the sole site of synthesis of vitamin D 
and skin is also one of its important targets.(20)  
The two major forms of vitamin D are vitamin D2 (ergocalciferol) and vitamin D3 
(cholecalciferol). They are naturally occurring, biologically inert pre-hormones. To become 
active they require two successive hydroxylations, first with 25-hydroxylase in the liver, and 
second with 1–hydroxylase in the kidney, to convert to the biologically active 1, 25-
dihydroxyvitamin D3 (calcitriol). Calcitriol and calcidiol (25-hydroxyvitamin D3) are active 
metabolic products of cholecalciferol.(20) 
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The human genome has 2,776 positions occupied by the vitamin D receptor (VDR). 
Therefore 10% of the human genes are responsive to vitamin D directly and/or indirectly.(21) It 
has been suggested that low levels of vitamin D may have important implications in the 
pathogenesis of psoriasis as it is involved in the keratinocyte growth and differentiation. It 
possibly has a role in the immunopathogenesis of psoriasis as it is now known to influence the 
immune functions of dendritic cells and T cells.(19)  
Psoriasis 
History 
In ancient Greece, skin diseases were categorised into psora, lepra and leichen. Psora 
meant itch. The Old Testament as well as the works of Hippocrates (460 -377 BC) clubbed 
leprosy as well as psoriasis together. The term ‘Psoriasis’ was first used by Galen (133-200 AD), 
though his description was not consistent with what is called psoriasis now. The patients were 
stigmatised similar to the lepers.(22) Dr. Robert Willan first recognized psoriasis as a specific 
clinical entity in 1809 and he described it accurately.(23) Finally, the works of Hebra and Gibert  
provided important distinction between various papulosquamous disorders.(22) Over years with 
the better understanding of the immune system and more and more reported systemic 
associations, it has evolved into a systemic disease rather than one that is confined to the skin.(4) 
Epidemiology 
The prevalence of psoriasis is varied in different parts of the world.  A recent systematic 
review on the global epidemiology of psoriasis (24) showed the following data (table 1). 
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Table 1 - Global epidemiology of psoriasis 
Epidemiology Prevalence Incidence 
Children 0% (Taiwan) to 2.1% (Italy) 40.8/100,000 person-years (United States) 
Adults 0.91% (United States) to 
8.5% (Norway) 
78.9/100,000 person-years (United States) 
to 230/100,000 person-years (Italy) 
 
In India, the prevalence of psoriasis ranges from 0.44 to 2.8%. It is twice as common in 
males as compared to females.(25) Depending on the age of onset, it can be classified into early 
onset or type 1 disease, when the disease onset is before 40 years and late onset or type 2 disease, 
when the age of onset is above 40 years.(26) 
There are several clinical types, the chronic plaque type being the commonest type 
reported in up to 90% of individuals with psoriasis. The commonest classification in practice is 
the one proposed by Griffiths.(27) 
Pathogenesis of psoriasis 
For long, psoriasis was considered to be a primary keratinocyte disorder. With the 
effectiveness of cyclosporine, which primarily targets T- cell function in psoriasis, there is a shift 
in focus from the keratinocyte to the various immunocytes.(3) Understanding the 
immunopathogenesis of psoriasis helps in the better understanding of the possible link between 
vitamin D and psoriasis.   
The key events involved in the pathogenesis of psoriasis are shown in figure 1. 
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AMP – Antimicrobial peptides; DNA – Deoxyribonucleic acid; RNA – Ribonucleic acid; IL – Interleukin; 
Th – T-helper; IFN - Interferon 
Figure 1 – Pathogenesis of psoriasis 
Upon injury such as in koebnerisation, antimicrobial peptides (AMPs) like cathelicidin 
LL-37 are produced by keratinocytes. These form complexes with self-nucleic acids (DNA and 
RNA) released by the injured cells. These complexes lead to the activation of plasmacytoid 
dendritic cells through endosomal Toll-like receptors 7 and 9. This leads to the production of 
type I interferons - IFN alpha and IFN beta. This results in maturation and differentiation of 
conventional dendritic cells. These conventional dendritic cells then stimulate autoimmune T 
cells through interleukin (IL)-23. These T cells are biased to produce T helper (Th) 17 cytokines 
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IL-17 and IL-22. These cytokines in turn induce expression of antimicrobial peptides in 
keratinocytes. This creates a sustained positive feedback loop. In addition, type I IFNs directly 
upregulate IL-22 receptors on keratinocytes. This increases their responsiveness to IL-22. 
Interleukin 22 inhibits the terminal differentiation and induces hyperproliferation of 
keratinocytes. This leads to epidermal hyperplasia which is a hallmark of psoriasis.(3) 
In the epidermis, 1, 25-dihydroxyvitamin D3 and the Vitamin D Receptors (VDR) appear 
to play a vital role in keratinocyte differentiation. In animal studies, VDR knockout mice 
exhibited reduced epidermal differentiation marker expression.(28) Vitamin D also has an 
influence on the immune functions of dendritic cells and T cells which are the key players in the 
pathogenesis of psoriasis.(19) 
 Furthermore, vitamin D analogues have been used successfully to treat skin conditions 
characterised by hyperproliferation, abnormal keratinocyte differentiation and epidermal 
inflammation.(29) 
Vitamin D and dendritic cells 
Vitamin D induces tolerogenic responses in conventional dendritic cells. Plasmacytoid 
dendritic cells from the blood rapidly infiltrate psoriatic skin and as mentioned earlier are 
important in the initiation of the immunological events in the pathogenesis of the disease. They 
express various proteins of the VDR pathway, including the vitamin D metabolising enzymes 
Cyp27B1 and Cyp24A1. Vitamin D receptor is transcriptionally active in plasmacytoid dendritic 
cells. It is found that vitamin D impairs the capacity of murine and human plasmacytoid dendritic 
cells to induce T-cell proliferation. It also impairs the secretion of T-helper 1 cytokine IFNγ. 
This effect is dependent on the expression of the VDR in the dendritic cells. It is proposed that 
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vitamin D signalling can act as a natural inhibitory mechanism on both conventional and 
plasmacytoid dendritic cells. This has various pathogenetic and therapeutic implications for 
psoriasis and other inflammatory skin diseases.(6) 
Vitamin D and T cells 
In all the stages of a T cell’s life, VDR expression and activity are found to be important. 
This ranges right from development to differentiation as well as the elicitation of effect or 
functions.(7) Vitamin D inhibits production of interleukin (IL)-2 and IL-6. It blocks the 
transcription of granulocyte-macrophage colony-stimulating factor mRNA  and interferon γ  and 
inhibits cytotoxic T cells and natural killer cell activity.(13) 
Vitamin D receptor gene polymorphism and the risk of psoriasis 
 The vitamin D receptor gene is localized to 12q12-14.(9) Several polymorphisms in VDR 
gene have been reported. Clinical response to 1 ,25-dihydroxyvitamin D3 in psoriasis has been 
found to correlate with the VDR mRNA expression level.(30) This in turn is influenced by the 
genotype of the VDR. Studies on the association between psoriasis and VDR gene have been 
performed in four polymorphisms - ApaI, BsmI, FokI or TaqI polymorphisms.(9)  
In Northeastern Han Chinese population (31) and Korean population (30) significant 
association was found between these polymorphisms and psoriasis. A study done in the 
population of eastern Croatia did not show association between these polymorphisms and 
psoriasis vulgaris.(32) Data based on meta-analysis showed that ApaI, TaqI polymorphisms in 
Caucasians,(9) ApaI and FokI polymorphisms in the Turkish populations and BsmI 
polymorphism in Asians were found to be associated with psoriasis.(33) 
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Role of vitamin D in the treatment of psoriasis 
 Calcipotriol (5)  
- It is a biologically active vitamin D analog which is safe and effective as a 
topical agent in the treatment of psoriasis. The exact mechanism of action is 
not known. 
-  1, 25-dihydroxyvitamin D3 receptor expression has been found to increase in 
epidermal basal keratinocytes during calcipotriol treatment. 
- Studies have shown that the effects on proliferation of epidermal keratinocytes 
and their differentiation were more than the effects on dermal inflammation. 
 Narrow band UVB therapy (34,35) 
- It is a well-established treatment modality for psoriasis.  
- It has been found to increase serum 25-hydroxyvitamin D (25-OH vitamin D) 
concentration significantly which is now postulated to be one of the possible 
mechanisms of action of phototherapy in the treatment of psoriasis.  
 Oral vitamin D(20)(36)(37) 
- Recent studies show a potential role of oral vitamin D3 supplementation in the 
treatment of psoriasis.  
- As compared to topical preparations, oral vitamin D is inexpensive and is 
easily available. 
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- Some authors recommend monitoring all psoriatic patients for vitamin D 
deficiency and maintaining normal levels of serum vitamin D. 
-  It has been proposed that vitamin D in pharmacologic doses could be 
considered a viable therapeutic option for psoriasis as monotherapy, or in 
combination with existing treatment options. (20) 
-  A case of adalimumab-induced psoriasis with resolution of lesions with high 
vitamin D3 doses has been reported. (36) 
-  It is proposed that high doses of vitamin D3 may compensate for inherited 
resistance to its biological effects. (37) 
 Analysis of 7 prospective trials of oral vitamin D3 supplementation in psoriasis showed 
its effectiveness and no major adverse effects. Potential side effects of oral vitamin D 
supplementation include hypercalcemia, hypercalciuria, and renal stones. Long term treatment 
can also cause bone demineralisation. Though the studies have reported an increase in calcium 
levels in blood and calciuria, none of the patients experienced adverse clinical events.(38)  
Vitamin D deficiency and psoriasis 
 There are recent studies showing association between vitamin D deficiency and psoriasis 
(Table 2). In 2011, Gisondi et al. from Italy published the first study showing higher prevalence 
of vitamin D deficiency in patients with psoriasis as compared to controls.(13) Subsequently 
studies by Orgaz-Molina et al. from Spain,(11,12) Hesham Abd El-Moaty Zaher et al. from 
Egypt,(39) Al-Mutairi et al from Kuwait (40) and Gutte et al. from India (17) showed a similar 
higher prevalence of vitamin D deficiency in psoriatic patients as compared to the controls. 
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The study by Gisondi et al. was a cross-sectional study conducted in Italy, which 
included 145 patients with chronic plaque psoriasis, 112 patients with rheumatoid arthritis 
(considered as positive controls) and 141 healthy controls (considered as negative controls). The 
prevalence of vitamin D deficiency (< 20 ng/mL) in patients with chronic plaque psoriasis was 
57.8% whereas in patients with rheumatoid arthritis and in healthy controls the prevalence was 
37.5% and 29.7% respectively (p< 0.001).(13) 
Orgaz-Molina et al. have published two case-control studies from Spain. In one of the 
studies, they compared the 25-OH vitamin D status of 43 Caucasian patients with psoriasis (with 
or without arthritis) with 43 age and sex matched Caucasian controls. The prevalence of vitamin 
D deficiency (<20 ng/mL) among psoriatic patients was 25.6% and that of the controls was 9.3% 
(p <0.043).(12) In their other study, Orgaz-Molini et al. analysed the 25-OH vitamin D levels of 
46 Spanish patients with psoriasis without arthritis and systemic treatment and 46 sex and age 
matched control subjects. The patients with psoriasis showed significantly lower level of vitamin 
D than controls (30.5 versus 38.3 ng/ml; p = 0.0001).(11)  
Hesham Abd El-Moaty Zaher et al. studied the vitamin D status of 48 biopsy-proven 
psoriatic patients and 40 age, sex and skin phototype- matched controls. Serum 25-OHvitamin D 
was significantly lower in patients than in controls (21.05 ± 3.66 ng/ml and  37.02 ± 5.06 ng/ml 
respectively; p = 0.000).(39) Al-Mutairi et al from Kuwait studied the serum vitamin D levels of 
one hundred consecutive patients with stable plaque psoriasis with body surface area 
involvement ≥10 % with no systemic treatment for 3 months prior to recruitment and compared 
with equal number of matched healthy volunteers. The serum vitamin D levels of psoriatic 
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patients were significantly lower than that of the healthy volunteers (31.5 ± 14.41ng/ml versus 
53.5±19.6 ng/ml with p <0.005).(40) 
Recently in June 2014, Gutte et al. published a prospective case-control study which was 
conducted in Mumbai on 50 patients with psoriasis and 50 age and sex matched controls. 
Patients with psoriasis had a 96% prevalence of vitamin D deficiency whereas among controls 
the prevalence was 64% (p = 0.001). They reported a mean vitamin D level of 13.55±3.43 ng/ml 
among the patients and in control group it was reported as 20.80±14.37ng/ml (p < 0.001).(17) 
However in a population-based study conducted in the United States, they did not find 
any significant difference in the prevalence of vitamin D deficiency as well as the mean serum 
vitamin D level between those with self-reported psoriasis and those without the disease. This 
study included 5,841 participants aged between 20  and 59 years, of which 148 self-reported 
psoriasis.(41)  
Thus the studies showing a higher prevalence of vitamin D deficiency among patients 
with psoriasis outnumber those that do not show such association. However the possibility of 
reporting bias cannot be excluded. 
Table 2 summarises the reported case-control studies on vitamin D deficiency and 
psoriasis. 
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Table 2 – Case-control studies on Vitamin D deficiency and psoriasis 
*Vit D deficiency – Vitamin D deficiency (<20 ng/ml) 
Parameter Orgaz-Molina 
et al. (11) 
Study-1 
Orgaz-Molina 
et al. (12) 
Study-2 
 
Gisondi et al. 
(13) 
 Hesham Abd 
El-Moaty 
Zaher et 
al.(39) 
Gutte et. 
al.(17) 
Country Spain Spain Italy Egypt India 
Vit d deficiency* 
[Frequency(%)] 
Cases 
Control 
p- value 
 
 
9 (19.6) 
0 (0) 
.000 
 
 
11 (25.6) 
4 (9.3) 
 0.043 
 
 
 
81 (57.8) 
42 (29.7) 
0.001 
 
 
12 (25) 
0 
0.001 
 
 
48 (96) 
32 (64) 
0.001 
Vitamin D level 
(mean±SD)ng/ml 
Cases 
Controls 
p- value 
 
 
30.52 ± 9.29 
38.31 ± 9.56 
0.000 
 
 
24.41 ± 7.80 
29.53 ± 9.38 
0.007 
 
 
20.7 ± 11.3 
37.1 ± 27.6 
0.001 
 
 
21.05±3.66 
37.02±5.06 
0.000 
 
 
13.55±3.43 
20.80±14.37 
0.001 
Overall 
prevalence of 
vitamin D 
deficiency in 
study subjects 
10.98% 17.4% 41.46% 13.64% 80% 
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Correlation of vitamin D level with psoriasis disease characteristics in various studies 
 Type 1 and type 2 psoriasis -  Park et al. in their study on vitamin D receptor gene 
polymorphisms (30) have reported a significantly higher frequency of ApaI 
polymorphism in patients with psoriasis than in healthy controls. This tendency was more 
accentuated in early onset psoriasis. The other studies on vitamin D and psoriasis did not 
have the vitamin D correlation with early and late onset psoriasis. 
 Duration of disease –  Orgaz-Molina et al.(11) as well as  Gisondi et al.(13) did not find 
any correlation of vitamin D level with the psoriasis disease duration. 
 Nail psoriasis -  The mean 25-OH vitamin D levels did not differ with the presence or 
absence of nail psoriasis in the study by Orgaz-Molina et al.(12) 
 Psoriatic arthritis - In the study by Orgaz-Molina et al., 7% of their patients had psoriatic 
arthritis and in the study by Gisondi et al., 40.7% of cases had psoriatic arthritis. In both 
the studies, there was no correlation between the presence of arthritis and vitamin D 
deficiency.(12,13) 
 Psoriasis area severity index (PASI) - Studies by Orgaz -Molina et al.(11) as well as 
Gisondi et al.(13) did not find any correlation of vitamin D level with PASI. 
 Body surface area involvement (BSA) - Similar to PASI, studies have not shown any 
correlation of vitamin D level with BSA involvement.(11,13)  
Correlation of metabolic syndrome related parameters with vitamin D in psoriatic patients 
in various studies 
Apart from the two case-control studies (11,12) mentioned earlier, Orgaz-Molina also 
studied the vitamin D level of 61 psoriatic patients without arthritis and 61 patients with psoriatic 
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arthritis. In the psoriatic patients without arthritis, there was inverse correlation between serum 
25-OH vitamin D levels and fasting glucose (r = −0.285; p = 0.026), total cholesterol (r = 
−0.440; p = 0.000), triglyceride (r = −0.280; p = 0.029) values, total cholesterol/high-density 
lipoprotein (r = −0.303; p =0.01) as well as low-density lipoprotein (r = −0.415; p = 0.001). This 
association was found to be statistically significant after adjusting for confounding factors in 
multivariate analysis for total cholesterol, glucose and low-density lipoprotein. However in 
patients with psoriatic arthritis, they could not find any association between serum 25-OH 
vitamin D levels and any metabolic parameter. They have suggested a possible protective effect 
of vitamin-D supplementation in psoriatic patients without arthritis on their metabolic 
profile.(10) 
The same authors, in one of their case control studies observed that the serum vitamin D 
levels did not correlate with blood pressure, HDL cholesterol, triglycerides or blood sugar levels. 
They also observed that psoriatic patients with BMI ≥ 27 kg/m2 had a higher risk of 25-OH 
vitamin D insufficiency (sensitivity - 82.3% and specificity - 51.7%) in the same study.(12) In 
their other case-control study, they observed that the patients with metabolic syndrome had 
significantly lower serum levels of 25-OH vitamin D than those without metabolic syndrome 
(24.1 ± 7.5ng/ml vs. 32.8 ± 8.9ng/ml, p = 0.007). They found a negative correlation between 
waist circumference, triglyceridemia, diastolic blood pressure, fasting glucose and the serum 
levels of 25-OH vitamin D.(11) 
Correlation of vitamin D with psoriasis after adjusting for confounders 
In the study by Gisondi et al., vitamin D deficiency was found to be associated with 
psoriasis independently of age, sex, body mass index, season of blood sampling, calcium and 
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PTH levels in the logistic regression analysis. However since it was a cross-sectional study 
design, a causal or temporal relationship between psoriasis and vitamin D deficiency could not 
be commented.(13) Orgaz-Molina et al. found a strong association between psoriasis and vitamin 
D insufficiency (<30 ng/mL), even after adjustment for confounders like body mass index 
(BMI), age, sex, Fitzpatrick skin phototype, dietary vitamin D intake, total sun-exposure using 
multivariate studies with binary logistic regression (Odds ratio 2.89, 95% Confidence interval 
1.02-7.64, p <0.03).(12) 
Interleukin 17 level and 25-OH vitamin D level in patients with psoriasis 
Since psoriasis is considered a prototypic Th17-mediated disease with a possible role 
played by vitamin D deficiency in its pathogenesis, Hesham Abd El-Moaty Zaher et al assessed 
the Interleukin 17 levels and 25-OH vitamin D level in patients with psoriasis and age and sex 
matched controls. Subjects with presence of any condition that might affect interleukin (IL)-17 
levels or serum vitamin D levels were excluded from the study. Mean serum 25-OH vitamin D 
was significantly lower in patients than in controls and serum IL-17 was found to be significantly 
higher in patients than in controls. No significant correlation was found between vitamin D and 
IL-17. This controversy was thought to be due to the smaller sample size and the multifactorial 
aetiology of psoriasis.(39)  
Interleukin-17 is proacanthotic, proangiogenic and proinflammatory. Vitamin D promotes 
differentiation and is antiangiogenic and anti-inflammatory. They seem to have important and 
opposing roles in innate and adaptive immunity. Vitamin D is believed to inhibit Th17 cell 
function and thus suppress its downstream cytokines. Their interaction may have a vital role in 
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the pathogenesis of psoriasis. Hesham et al. proposed that low vitamin D levels could be 
attributed to the inflammatory milieu that was created by IL-17.(39) 
Correlation of vitamin D level and cathelicidin level in psoriatic patients 
  Cathelicidin (LL-37) is known to initiate an autoimmune response in the pathogenesis of 
psoriasis by activating plasmacytoid dendritic cells of skin.(42) Vitamin D is now known to 
regulate the expression of cathelicidin. A study estimating the levels of cathelicidin and vitamin 
D in psoriasis patients with co-morbidities in comparison with matched healthy controls. The 
serum vitamin D levels were significantly lower in patients than in controls and the levels of 
serum cathelicidin were significantly higher.(40) 
Metabolic syndrome – The common link between vitamin D deficiency and psoriasis 
Metabolic syndrome was first described by Gerald Reaven, an endocrinologist in1988. 
The original description was the clustering of four conditions namely glucose intolerance, 
hypertension, central obesity and dyslipidemia in one individual that increased the risk of 
cardiovascular disease.(43) According to the new International Diabetes Federation: (44) 
• One fourth of world’s adults have metabolic syndrome. 
• Individuals with metabolic syndrome have two times higher risk of mortality and three 
times more risk of a cardiac attack or stroke when compared to those without the 
syndrome. 
• Individuals with metabolic syndrome have a five times higher risk of developing type 2 
diabetes. 
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•  Out of the 200 million individuals with diabetes globally, up to 80% are likely to die of 
cardiovascular disease. 
• This puts diabetes and metabolic syndrome way ahead of HIV/AIDS in terms of  
morbidity and mortality, however the problem is not as well recognised. 
Metabolic syndrome and psoriasis 
There are reports suggesting an association of metabolic syndrome with vitamin D 
deficiency as well as with psoriasis vulgaris. Metabolic syndrome shares some common 
immunological mechanisms with psoriasis. Since 1950, there are various studies which describe 
the link between individual components of metabolic syndrome with psoriasis.(43) 
The intra-abdominal fat cells secrete adipocytokines thus acting as an endocrine organ. 
These adipocytokines affect glucose metabolism, promote inflammation and also affect vascular 
endothelial biology. Visceral adiposity is found to be associated with elevated levels of 
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and plasminogen activator inhibitor 
type1. The levels of TNF-α, IL-6 and plasminogen activator inhibitor type1 have been found to 
be elevated in psoriasis as well. Leptin is a hormone secreted by adipocytes. It plays a pro 
inflammatory role in regulating cytokine expression which modulates the Type 1 and Type 2 
helper cells. Hyperleptinemia is found to be associated with the development of metabolic 
syndrome. Elevated levels of leptin has been observed in patients with psoriasis.(45) Adiponectin 
is another circulating hormone that is produced by adipocytes. It suppresses the production of 
TNF-α, IL-6 and INF-α and thereby has anti-inflammatory activity. It has anti atherogenic 
effects and improves insulin sensitivity. Visceral obesity causes hypoadiponectinemia, which in 
turn increases the cardiovascular risk. The proinflammatory cytokines TNF- α, IFN- α, IL-1, and 
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IL-6, favor the development of psoriasis as well as atherosclerosis. Osteopontin is an 
inflammatory glycoprotein which exerts a Th1 cytokine effect. It is thought to play a role in 
atherogenesis. Psoriasis is found to be a risk for elevated levels of osteopontin.(46) 
Hyperinsulinemia in metabolic syndrome has been thought to promote psoriasis 
susceptibility and / or severity by facilitating angiogenesis and chronic inflammation. In addition, 
certain pleiotropic genetic loci, e.g., CDKAL1, PSORS2-4, and ApoE4 have been thought to 
play a role in the shared genetic susceptibility to both metabolic syndrome and psoriasis.(47,48) 
Obesity is considered to be a risk factor for future development of psoriasis based on several 
studies and the estimated new cases being attributable to obesity is 30%. Similarly studies show 
that psoriasis patients are also prone to the future development of components of metabolic 
syndrome.(15) 
April W. Armstrong et al. performed a systematic review and meta-analysis on the 
epidemiologic associations between metabolic syndrome and psoriasis. The pooled odds ratio for 
metabolic syndrome among psoriatic patients was 2.26 (95% confidence interval 1.70-3.01) 
when compared with general population. There are no studies on the incidence of metabolic 
syndrome among psoriatic patients. The patients with more severe psoriasis were found to have 
greater odds of metabolic syndrome as compared to those with milder psoriasis.(49) 
In a study reported from south India by Shraddha Madanagobalane et al., the prevalence 
of metabolic syndrome in psoriatic patients was 44.1% whereas in controls it was 30%, the 
difference being statistically significant (p value = 0.025). The prevalence of triglyceridemia in 
patients was 33.9% and in controls was 20.8% (p value = 0.011) and that of abdominal obesity 
was 34.7% and 32.5% (p value = 0.035) respectively. There was no significant difference in the 
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HDL levels and presence of hypertension among patients and controls. In that study, there was 
no correlation between the duration and the severity of psoriasis with metabolic syndrome. They 
suggested that all patients with psoriasis irrespective of the disease severity must be evaluated for 
metabolic syndrome.(45) 
There are also several studies on cardiovascular events in patients with psoriasis. A meta-
analysis of both cohort studies and cross-sectional studies showed an increased risk of 
myocardial infarction with odds ratio of 1.25 (95% CI 1.03–1.52) in psoriasis and 1.57 (95% CI 
1.08–2.27) in psoriatic arthropathy when compared with the general population. The risk was 
found to be more with severe psoriasis and psoriasis with early onset.(50) 
Vitamin D and metabolic syndrome 
Common obesity and metabolic syndrome has been proposed to result from an abnormal 
adaptive winter response. A fall in vitamin D is proposed to be the stimulus for the winter 
response. Vitamin D synthesis is dependent on the absorption of UVB radiation. It has been 
proposed that vitamin D evolved as a UVB sensitive photoreceptor in primitive organisms and it 
signals changes in sunlight intensity. A fall in vitamin D is thought to evoke the stimulus for the 
winter response, which causes an accumulation of fat mass and induction of a winter 
metabolism. The increasing prevalence of obesity can probably be reversed by improving the 
vitamin D status.(51) 
Vitamin D is thought to play a role in lipogenesis as well as lipolysis regulation as 
suggested by the presence of vitamin D receptors in adipocytes. Wortsman et al. studied the role 
of obesity in altering the production of vitamin D3 in the skin as well as its role in intestinal 
absorption of vitamin D2 (ergocalciferol). In their study obese subjects had lower basal 25-
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hydroxyvitamin D levels and higher parathyroid hormone levels than did age matched controls. 
They evaluated the blood vitamin D3 levels 24 hours after whole body irradiation. The 
incremental increase in vitamin D3 was 57% less in obese patients than in controls. The content 
of 7-dehydrocholesterol (vitamin D3 precursor) as well as its conversion to previtamin D3 post 
irradiation in vitro did not differ significantly between groups. Both the groups were given 
50,000 IU of oral vitamin D2. BMI inversely correlated with peak serum vitamin D2 levels after 
vitamin D2 intake. They concluded that obesity associated vitamin D insufficiency is probably 
due to decreased bioavailability of vitamin D3 from dietary and cutaneous sources because of its 
deposition in body fat compartments.(52) 
In a study from Saudi Arabia aimed at determining whether vitamin D status correction 
could reverse the already established manifestations of metabolic syndrome, they recruited a 
total of 59 adults (31 male, 28 female) who were overweight and obese without diabetes. This 
was a 1-year prospective, interventional study. Anthropometry measures were recorded. Fasting 
blood glucose, lipid profile, serum 25-hydroxyvitamin D level, calcium and phosphorous 
concentrations were measured. Subjects were advised to increase the dietary intake of vitamin D 
rich food, to do exercise regularly and regularly expose them to sunlight. All measurements were 
checked 6 and 12 months later. The overall prevalence of metabolic syndrome had decreased 
from 25.2% to 13.0%. This was mainly contributed by a parallel decrease in the prevalence of 
triglycerides, low HDL cholesterol and hypertension. They proposed that optimisation of vitamin 
D status through increased intake of a vitamin D rich diet and increased sun-exposure can lead to 
an improved cardio metabolic profile. This offers a promising non-pharmacologic approach to 
the prevention of metabolic syndrome.(53) 
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Vitamin D deficiency in other disorders 
  Vitamin D deficiency has been studied in the context of various other disorders, some of 
which are listed below. 
 Cardiovascular disease (54,55) - survival was found to be significantly lower in subjects 
with vitamin D deficiency.  
 Glucose intolerance, type 1 & type 2 Diabetes mellitus (56,57) -  increased risk for 
insulin resistance and metabolic syndrome with vitamin D deficiency and correlation of 
glycaemic control with vitamin D levels. 
 Autoimmune disorders (58) like autoimmune encephalomyelitis, multiple sclerosis, 
rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease - loss 
of self-tolerance with vitamin D deficiency. 
 In  human immunodeficiency virus (HIV) infection (59) – increased risk of vitamin D 
deficiency and decreased bone mineral density  in patients on highly active antiretroviral 
therapy (HAART) . 
 Critical care population (19) – increased mortality with vitamin D deficiency. 
 Other dermatological conditions (60–62) like urticaria, vitiligo, atopic dermatitis, etc.- 
correlation with vitamin D deficiency noted. 
Factors affecting the vitamin D status 
Vitamin D deficiency/ insufficiency are reported in epidemic proportions worldwide. It is 
estimated that worldwide one billion people have vitamin D deficiency or insufficiency.(63) 
There is slight variation in the interpretation of 25-OH vitamin D serum levels as by 
various organisations.  The recommendation by various organisations (64) is as shown in table 3: 
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Table 3 – 25-hydroxyvitamin D range guidelines from various organisations 
 Endocrine 
Society 
Food and 
Nutrition Board 
Vitamin D 
Council 
Testing 
Laboratories 
Deficient 0-20 ng/ml 0-11 ng/ml 0-30 ng/ml 0-31 ng/ml 
Insufficient 21-29 ng/ml 12-20 ng/ml 31-39 ng/ml … 
Sufficient 30-100 ng/ml >20 ng/ml 40-80 ng/ml 32-100 ng/ml 
Toxic --- --- >150 ng/ml --- 
 
Cutaneous synthesis of vitamin D 
Cutaneous synthesis of vitamin D with exposure to ultraviolet radiation accounts for 
more than 90% of the total vitamin D synthesis in the body.(12) Large quantities of the 
provitamin D3 molecule 7-dehydrocholesterol is produced in the skin. It is incorporated into the 
lipid bilayer of plasma membrane of cells in epidermis and dermis. With sun-exposure, UVB 
radiation in the range of 290–315 nm is absorbed by this 7-dehydrocholesterol. The energy thus 
absorbed leads to break and rearrangement of chemical bonds within the 7-dehydrocholesterol 
molecule. This results in the formation of previtamin D3. This previtamin D3 rapidly undergoes 
thermally-induced transformation to form vitamin D3. Previtamin D3 and vitamin D3 continue 
to engage in absorption of UV radiation in a wide wavelength range. This continuous absorption 
of UV radiation results in breakdown of previtamin D3 and vitamin D3 molecules into 
photoproducts that are biologically inert.(65) During prolonged sun-exposure this results in a 
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steady state in which only 10–15% of 7-dehydrocholesterol is converted to previtamin D3.(66) 
This prevents the synthesis of toxic levels of vitamin D3 during prolonged sun-exposure. 
Vitamin D3 that is synthesized in the skin is released from the plasma membrane which 
enters the systemic circulation. It is bound to vitamin D-binding protein once it reaches the 
circulation.(67) Serum vitamin D3 level peaks 24 to 48 hours after sun-exposure. The serum 
half-life of vitamin D3 ranges from 36 to 78 hours and the level decreases exponentially.(68,69) 
Since it is fat-soluble, vitamin D3 is taken up by adipocytes and is stored in subcutaneous as well 
as omental fat for later use. This prolongs its total-body half-life to nearly two months.(70) 
It is further metabolised to 25-OH vitamin D in the liver and 1, 25-dihydroxy vitamin D 
in the kidneys by subsequent hydroxylations to be converted into active form. 
This biosynthesis of vitamin D in the skin is affected by the following factors: 
 Exposure to ultraviolet radiation, which is influenced by factors such as the pollutants in 
the atmosphere and solar zenith angle which is determined by the time of the day, time of 
the year and latitude 
 Cutaneous factors such as clothing, sunscreen usage, Fitzpatrick skin phototype and 
temperature of the skin (63) 
- Lightweight, loosely woven, white, non-synthetic fibers such as cotton and linen 
are less effective at blocking UV radiation than thick, densely woven, black and 
fabrics such as wool, silk, nylon and polyester 
- A sunscreen with sun protection factor 8, if applied in an ideal way is able to 
prevent the absorption of ultraviolet radiation by 95% 
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- Darkly pigmented skin with higher concentration of melanin require longer 
duration to synthesize an equivalent amount of vitamin D3 as compared to 
individuals with lightly-pigmented skin.(71) 
Dietary factors 
 The Food and Nutrition Board recommended dietary allowance (RDA) for infants below 
one year of age is 400 IU daily. Between 1 and 70 years of age, the RDA is 600 IU. For elderly 
over 70 years of age, it increases to 800 IU.(72) 
 The food and nutrition board recommended dietary allowance is as shown in table 4 
below: 
Table 4 - The Food and Nutrition Board recommended dietary allowance 
 
Age group RDA 
< 1 year 400 IU 
1 to 70 years 600 IU 
>70 years 800 IU 
 
Very few food items contain vitamin D. Fish liver oils and flesh of fatty fish such as 
mackerel, salmon, tuna etc. are the best sources of vitamin D. Small quantities of vitamin D are 
also found in beef liver, egg yolk and dairy products. In some countries milk and few other food 
stuff are fortified with vitamin D by law.(72) However in India, dairy products are very rarely 
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fortified with vitamin D and the very few products that are fortified are not priced within the 
common man’s reach.(73) 
Vitamin D deficiency in India 
 
 Vitamin D deficiency has a prevalence of 70 to 100% in the Indian subcontinent. It 
prevails as an epidemic, prevalent in both rural and urban settings, and all socioeconomic groups 
and geographic strata. In India, dairy products are rarely fortified with vitamin D and the culture 
and many socioreligious practices do not favor adequate sun-exposure despite the presence of 
plentiful sunshine. Subclinical vitamin D deficiency is thought to play an important role in the 
high prevalence of rickets, cardiovascular diseases, diabetes, osteoporosis, cancer and infections 
like tuberculosis in India.(73) The following factors are thought to play a major role in the high 
prevalence of vitamin D deficiency.(74) 
 Low intake of low dietary vitamin D and calcium can be attributed to changing food 
habits. 
 High fibre diet containing phytates and phosphates can deplete vitamin D stores and 
increase calcium requirement. 
 Genetic factors like the presence of increased 25(OH) D-24- hydroxylase that degrades 
25-OH vitamin D to inactive metabolites. 
 Increase in serum 25-OH vitamin D in response to treatment depends on heritability of 
vitamin D binding protein. 
 The average number of hours spent outdoor have decreased which prevents adequate sun- 
exposure especially in the urban Indians. 
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 Increase in pollution can hinder the ultraviolet rays from adequate synthesizing of 
vitamin D in the skin. 
 Certain religious practices like “Burqa” and the “pardah” system do not allow adequate 
sun-exposure. 
 Absence of adequate spacing between pregnancies can cause vitamin D deficiency in the 
mother and fetus. 
 
Use of vitamin D in various disorders 
 There is growing literature on the use of vitamin D in various disorders. A Mayo Clinic 
monograph on vitamin D use has categorised the scientific evidence of its use as given 
below(75): 
A - Strong scientific evidence 
B - Good scientific evidence 
C - Unclear scientific evidence 
D - Fair scientific evidence against use (might not work) 
F - Strong scientific evidence against use (likely does not work) 
A 
- Familial hypophosphatemia 
- Fanconi syndrome 
- Osteomalacia 
- Rickets 
- Psoriasis 
- Hypocalcemia-post parathyroidectomy 
- Secondary hyperparathyroidism due to  deficiency of vitamin D 
B 
- Dental Cavities 
- Fall prevention and fracture reduction 
- Muscle weakness / myalgia 
- Osteoporosis 
- Renal osteodystrophy 
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In summary the association between the vitamin D status and psoriasis could be relevant 
for several reasons: 
a) It is implicated in keratinocyte differentiation, immune function of T-cells and dendritic 
cells having important role in the pathogenesis of psoriasis. 
C 
- Asthma 
- Autoimmune diseases  including  Crohn's disease, rheumatoid 
arthritis and multiple sclerosis 
- Chronic kidney disease – to increase bone density 
- Cancer prevention (colorectal, breast, prostate, other) 
- Alzheimer's disease 
- Infertility 
- Fibromyalgia 
- Fracture prevention and treatment 
- Hepatic osteodystrophy 
- Hypertension 
- HIV 
- Infectious diseases 
- Increasing lifespan 
- Inflammatory bowel disease 
- Loose teeth 
- Mood disorders including  seasonal affective disorder,  
premenstrual syndrome and depression 
- Multiple sclerosis 
- Muscle wasting 
- Myelodysplastic syndrome 
- Osteoarthritis 
- Osteogenesis imperfecta 
- Steroid induced osteoporosis 
- Respiratory tract infection prevention 
- Senile warts 
- Sexual dysfunction 
- Stroke 
- Tuberculosis 
- Type 1 & type 2 diabetes mellitus 
- Vitiligo 
- Post menopause weight gain 
D 
- Atopic eczema 
- Prostate cancer treatment 
- Heart disease 
- Hypercholesterolemia 
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b) It has a role in the treatment of psoriasis. 
c) It is associated with metabolic syndrome which is known to be common in individuals 
with psoriasis. 
d) Vitamin D receptor gene polymorphisms have been observed in patients with psoriasis. 
Thus there appears to be a strong association between vitamin D status and psoriasis 
vulgaris. There were no Indian studies on the association between vitamin D status and psoriasis 
vulgaris when we commenced this study. 
Considering the high prevalence of vitamin D deficiency in India, a study with larger 
sample size would be needed. However due to time and financial constraints, this study was 
designed as a pilot study to help us design further larger trials. 
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Materials and methods 
 
Study Design: 
This was a hospital based, cross-sectional observational case-control study. 
Setting: 
The study was done in the Dermatology, Venereology and Leprosy outpatient department 
of our tertiary care hospital. It is a 2122 bedded hospital located in Tamil Nadu, south India.  
Study period: 
The study was conducted between December 2013 and August 2014.  
Participants: 
All consecutive patients hailing from Tamil Nadu with chronic plaque psoriasis as the 
cases and those with non-psoriatic non-photosensitive minor skin problems like warts, naevi, 
seborrheic keratosis etc. as the controls, attending Dermatology outpatient department during the 
study period (between December 2013 and August 2014) were considered for eligibility into the 
study. Patients from only Tamil Nadu were recruited in the study to avoid regional variability in 
the sun-exposure affecting the vitamin D level. Tamil Nadu extends roughly between the 8° 04' 
N latitude and the 78° 0' E longitude.  
We did not take a community based healthy controls since a community based control 
would be homogenous in terms of being either a rural area or an urban area. If a rural area is 
selected, the chances of most people working outdoor and thereby increased sun-exposure would 
be high. On the other hand, if an urban area is selected, indoor workers may be more and this 
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would affect the vitamin D level. Hence an OPD based control group coming for minor skin 
diseases were taken as controls to maintain a heterogenous group as the cases. 
Inclusion criteria for cases: 
• Age ≥ 18 years and ≤ 65 years 
• Chronic plaque psoriasis patients with or without arthritis attending Dermatology 
outpatient department 
• Patients from Tamil Nadu 
 
Exclusion Criteria for cases: 
• Psoriasis patients in remission (without skin lesions) 
• Oral vitamin D therapy (past or present), topical vitamin D or phototherapy or systemic 
therapy for psoriasis in the last 3 months 
• Other clinical forms of psoriasis like erythrodermic psoriasis, pustular psoriasis 
• Presence of chronic inflammatory diseases and  autoimmune disorders such as vitiligo, 
immunobullous disorders, multiple sclerosis, inflammatory bowel disease, rheumatoid 
arthritis, insulin dependent diabetes mellitus, lupus erythematosus, cutaneous lymphoma, 
renal disorders, non-melanoma skin cancer or any other cancer 
• Patients not willing to participate in the study 
• Patients who were not able to give informed consent 
• Pregnancy and lactation 
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Inclusion criteria for controls: 
• Age ≥18 years and ≤ 65 years 
• Patients with non-psoriatic, non-photosensitive minor skin disorders attending 
Dermatology outpatient department 
• Patients from Tamil Nadu 
 
Exclusion criteria for controls: 
• Vitamin D therapy in the past or present 
• Presence of chronic inflammatory diseases and autoimmune disorders such as vitiligo, 
immunobullous disorders, multiple sclerosis, inflammatory bowel disease, rheumatoid 
arthritis, insulin dependent diabetes mellitus, lupus erythematosus, cutaneous lymphoma, 
renal disorders, non-melanoma skin cancer or any other cancer 
• Patients not willing to participate in the study 
• Patients who were not able to give informed consent 
• Pregnancy and lactation 
 
The process that was followed in our study for the recruitment of cases and controls is shown in 
figure 2. 
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Figure 2 Algorithm showing the study methodology 
  
Patients from Tamil Nadu 
attending Dermatology OPD 
aged between 18 and 65 years  
Clinical diagnosis 
of psoriasis 
Non-psoriasis 
skin problem 
Chronic 
plaque 
psoriasis with 
or without 
arthritis 
- Other forms of psoriasis like 
erythrodermic, pustular 
psoriasis etc. 
- Autoimmune disorders 
- Topical vitamin D therapy or 
phototherapy in the past 3 
months or systemic therapy in 
the past 3 months 
- Vitamin D therapy in the past 
- Not willing to participate 
 
- Photosensitive 
skin disorders 
- Autoimmune 
disorders 
- Vitamin D therapy 
in the past 
- Not willing to 
participate 
Yes  No  
Excluded from 
the study 
PASI / body surface 
area assessment, 
height, weight, BP and 
waist circumference 
Age and sex 
matching compared 
to cases 
Vitamin D, fasting 
lipid profile, AC/PC 
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Methodology: 
The diagnosis of psoriasis was made based on the clinical features. All the patients, with 
psoriasis and controls with minor skin problems, who fulfilled the inclusion criteria, were 
enrolled into the study after obtaining informed consent. (Annexure – 1 & 2) 
Age and sex matching was done between the subjects in patient and control group. 
Subjects of the same gender with age difference of ±2 years were considered as a matched pair. 
The details pertaining to the study collected from the psoriasis patient group and from the 
control group was documented in separate clinical research proforma. (Annexure – 3 & 4) 
Demographic details: 
Demographic details regarding age and gender of the subjects, area of residence and 
occupation were recorded. 
History pertaining to parameters likely to affect vitamin D: 
1. Age of the subject – as reported by the subjects / as in Hospital records. 
2. Gender 
3. Residence - whether urban, semi-urban or rural. 
4. Fitzpatrick skin type (76) 
- Always burn, never tan – skin type I 
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- Usually burn, tan less than average or with difficulty – skin type II 
- Tans after initial burn – skin type III 
- Burns minimally, tans easily – skin type IV  
- Rarely burns, tans darkly easily – skin type V 
- Never burns, always tans darkly – skin type VI 
5. Occupation – Whether the occupation was indoor or outdoor was recorded. Those 
who were not employed were categorised under indoor if they spent less than 30 
minutes per day for outdoor activities. 
6. Average sun-exposure per day – The average sun-exposure per day in week days as 
well as in the weekends was documented and the average sun-exposure per week in 
hours was calculated. 
7. Type of clothing - The study subjects were enquired on their clothing pattern while 
outdoor. They were categorised based on the area of photo-exposed skin as below: 
a. Minimal - if only face is photo-exposed (e.g. women wearing 'Burqa’) or only 
face, hands and feet are photo-exposed (e.g. those wearing full sleeved shirts 
and full trousers) 
b. Moderate - if face, most of the upper limbs and feet are exposed. (e.g. Those 
wearing half sleeved shirts and trousers or saris) 
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c. Maximal - if face, upper limbs, most of trunk and most of lower limbs 
exposed (e.g. Agricultural field workers wearing only dhoti) 
8. Sunscreen usage pattern – The subjects were enquired as to whether they used 
sunscreen and if they used, the frequency of usage and the sun protection factor (SPF) 
of the sunscreen were documented. The frequency of usage was categorised into 1 – 
Always, 2 – Mostly, 3- Occasional and 4 – Never. 
9. Smoking – The subjects were enquired as to whether they smoked. If there was 
history of smoking, the pack years was calculated by multiplying the number of years 
of smoking by the number of packs of cigarettes smoked in a day. For example, one 
pack year = smoking 20 cigarettes (1 pack) per day x 1 year or 40 cigarettes /day for 
half a year.(77) 
10.  Alcohol intake – The subjects were enquired as to whether they consumed alcohol. If 
they consumed alcohol, the quantity of alcohol intake per week (in ml.) and the 
number of years of alcoholism was documented. 
11. Average quantity of intake of fish and milk - Average quantity of vitamin D in non-
fortified milk was taken as 40 IU in 1000ml.(78) The average vitamin D in 75g of 
fish was taken as 250 IU.(79) 
  
41 
 
History pertaining to psoriasis: 
1. Age at onset of psoriasis as recollected by the patient when he or she noticed the first 
plaque was documented. The patients were categorised into type 1 or early onset psoriasis 
when the onset was before 40 years of age and type 2 when the onset was at or after 40 
years of age.(26) 
2. The disease duration was calculated and was categorised into < 1 year, 1 to 5 years and > 
5 years.(45) 
3. Data regarding any seasonal variation of the disease activity as observed by the patient. 
4. Social avoidance – Patients were enquired if they avoided social activities. If they gave a 
positive response, then the reasons were categorised into 1 - social, 2 – disability, 3 – 
others. 
5. Family history of psoriasis  
6. Necessary information regarding past treatment was also collected. 
7. Presence or absence of arthritis was documented. 
Clinical examination: 
1. The anthropometric measures such as height (cm) and weight (kg) were recorded. 
2. The body mass index was calculated as weight (kg) divided by height (m) squared. 
Definitions for overweight and obesity were based on the WHO definitions for 
overweight and obesity in adults, that is BMI greater than or equal to 25 is overweight 
and greater than or equal to 30 is obesity. (80) 
3. Waist circumference measurement was made (in cm) at the approximate midpoint 
between the lower margin of the last palpable rib and the top of the iliac crest.(81) 
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4. Blood pressure - Systolic and diastolic blood pressure (BP) were measured after a 5-
minute rest and repeated again after a 10-minute interval. Average systolic and diastolic 
blood pressure was calculated. 
5. The patient’s skin, scalp and nails were examined and the details were recorded. 
6. Psoriasis severity was documented in terms of body surface area involvement. In case of 
controls, the dermatological diagnosis and surface area of involvement were documented. 
7. Joint examination was done and CASPAR (82) criterion, as below, was used for the 
diagnosis of psoriatic arthropathy. A minimal score of ≥ 3 was needed for making a 
diagnosis of psoriatic arthropathy. 
1 Skin psoriasis 
Present - 
Past - 
 
2 
1 
 Family history, if patient not affected 1 
2 Nail (pits / onycholysis / hyperkeratosis)            1 
3 Dactylitis                1 
4 Rheumatoid factor negative                               1 
5 Juxtaarticular new bone formation                    1 
8. The type of arthritis was classified based on the Moll and Wright’s classification (82) as 
given below: 
a. symmetric polyarthritis resembling rheumatoid arthritis 
b. asymmetric oligoarthritis 
c. arthritis mutilans 
d. spondyloarthritis 
e. distal interphalangeal predominant 
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9. Nail involvement was documented and NAPSI (Annexure – 3) score was calculated. 
Severity of psoriasis: 
The extent of the disease was measured by the body surface area (BSA) involved 
according to Wallace’s formula of 9 in adults.(83) The disease severity was classified into mild, 
moderate and severe, if the percentage of BSA involved was < 3%, 3-10% and > 10% 
respectively.(84)  
The PASI scoring (Annexure – 3) was done for chronic plaque psoriasis as a measure of 
clinical severity. The score ranges from 0-72 representing no involvement to complete 
involvement (erythroderma) of the severe possible degree.  
The severity of psoriasis was graded, based on PASI score into mild (< 7), moderate (7 - 
12) and severe if the PASI score was >12.(85)  
Laboratory parameters: 
1. Vitamin D level (25-hydroxyvitamin D) was measured for all the patients and controls. It  
was considered normal if the value was ≥ 30 ng/ml, deficient – if ≤ 20 ng/ml and 
insufficient if between 20 -30 ng/ml.(64) Serum 25-OH vitamin level was determined by 
chemiluminescence method in the clinical biochemistry department of our hospital. 
2. Fasting blood sugar and 2 hour post prandial blood sugar were measured for all subjects. 
3. Fasting lipid profile was measured for all subjects. 
4. The diagnosis of metabolic syndrome was made based on the criteria proposed by the 
new International Diabetes federation. (Annexure - 5)(44) Central obesity was taken as 
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the essential criteria. Ethnicity specific waist circumference cut-off for central obesity as 
recommended for Indians i.e. ≥ 90 cm for men and ≥ 80 cm for women was used. Of 
those who were noted to have central obesity, if they fulfilled any two of the four below 
mentioned criteria, they were diagnosed to have metabolic syndrome. 
 Systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg or known hypertensives on 
treatment 
 Raised triglyceride levels( ≥150 mg/dl) or on treatment for dyslipidemia 
 Low HDL cholesterol level for their gender (< 40mg/dl for males and  < 50mg/dl 
for females) or on treatment for dyslipidemia 
 Elevated fasting blood sugar level (≥ 100 g/dl) or known diabetics on treatment 
5. In patients with active arthropathy, C-reactive protein, Rheumatoid factor and joint X – 
ray were done. 
 
Sample size: 
The sample size of the study was calculated as explained below: 
For 5% error and 80% power, the sample size required would be  
7.84 x [p1 (1-p1) + p2 (1-p2)] 
n =  --------------------------------------- 
 (p1 – p2)2 
 
p1 - prevalence of vitamin D deficiency in the control group 
p2 - prevalence of vitamin D deficiency in the psoriasis group 
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The sample size was calculated based on an Italian study published by Gisondi et al.,(13) as there 
were no published Indian studies on the prevalence of vitamin D deficiency in patients with 
psoriasis when this study was planned. 
Based on the previous study - 
p1 was taken as 29.7% (30%) 
p2 was taken as 57.8% (58%)   
7.84 x [0.3 (1 – 0.3) + 0.58 (1 – 0.58)] 
n = ------------------------------------------------- 
  (0.3 – 0.58) 2 
 
  
  = 45.3 
   = 45 
 
Therefore a minimum of 45 patients were required in each arm. 
 In India, the prevalence of vitamin D deficiency is high (73,74) and it could be a limitation of 
this study. However due to financial constraints, this was planned as a pilot study to help us in 
further planning of larger trials. 
Statistical methods: 
Data were entered in EpiData version 3.1, and analysed using the software STATA 
version 13.0.  Continuous variables were summarised using mean and standard deviations and 
categorical variables were summarised using frequencies along with percentages. The t–test was 
used to check the group mean differences. Chi square test was used to check the association 
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between categorical variables. Conditional logistic regression was performed taking the vitamin 
D deficiency and disease status as outcome. Univariate analysis was done to check the impact of 
predictors. A linear regression was performed having the log transformed vitamin D levels as 
outcome.  Skewed variables were log transformed and back transformed and interpreted as 
percentage change. A multivariate analysis was performed adjusting for skin type, occupation, 
locality and metabolic syndrome with the important predictors. 
Study approval: 
This study was approved by the Institutional Review Board. (IRB No - 8593[observe]) 
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Results 
 
During the study period (December 2013 to August 2014), there were 352 patients who 
were diagnosed to have psoriasis. Of those 352 patients, 53 patients with chronic plaque psoriasis 
who fulfilled the inclusion criteria and willing for the study were recruited, after obtaining 
informed consent. Forty-seven patients with non-psoriatic, non-photosensitive minor 
dermatological ailments fulfilling the inclusion criteria for controls were recruited after obtaining 
informed consent. 
A total of 100 subjects (53 patients and 47 controls) were recruited into the study. Of the 
53 patients, only 45 had given blood sample for vitamin D testing. Age and sex matching was 
done only for those 45 patients whose vitamin D results were available. Hence finally there were 
45 cases and 45 age and sex matched controls. These 45 cases and 45 age and sex matched 
controls were taken for the final analysis (Annexure - 6). 
The flow chart (figure 3) shows patient recruitment process followed in our study. 
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Figure 3: Flowchart showing the protocol followed for patient recruitment 
1. Baseline characteristics 
1.1. Age and gender distribution 
 The age of the subjects ranged from 18 years to 65 years. The mean age of the cases was 
41.62 years (± 37.92). The mean age of the control group was 41.29 years (± 37.56). 
There were 26 males (57.78%) and 19 females (42.22%) in both the study groups (figure 
4). Since matching was done, there was no difference between both the groups with respect to 
age and gender distribution (p = 0.90 for age and p = 1 for gender). The male: female ratio in our 
study group was 1.38: 1. 
Age and Sex matching
45 cases 45 controls
Patients with Vitamin D results
Patients who fulfilled criteria and consented for the study
53 cases 47 controls
Patients attending Dermatology  OPD with diagnosis of psoriasis
(n=352)
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Figure 4: Gender distribution of the study subjects 
 
1.2. Locality and occupation distribution 
Majority of our study subjects (57.78%) were from semi-urban areas. There was only one 
individual from urban set up (1.11%) and 37 (41.11%) were from rural set up. Among the cases, 
there were 21 (46.67%), 23 (51.11%) and 1 (1.11%), from rural, semi-urban and urban set up 
respectively. Among the controls there were 16 (35.56%) and 29 (64.44%) from rural and semi-
urban setup respectively. There was no statistical difference between the patients and controls in 
Male
58%
Female
42%
Gender distribution
(Male:Female = 1.4:1)
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relation to the locality (p=0.31). Figure 5 shows the distribution of cases and controls based on 
locality. 
 
Figure 5: Distribution of study population based on locality 
 Nineteen (42.22%) in each arm were engaged in outdoor occupation and 26 (57.78%) in 
each arm were engaged in indoor activities. Though matching with respect to occupation was not 
intentionally done, both the arms had exactly the same number of subjects working indoors and 
outdoors, as shown in figure 6. 
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Urban 2.22% 0
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Rural 46.67% 35.56%
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Figure 6: Type of occupation among the study subjects 
 
1.3. Skin type and type of clothing 
 The study subjects had either Fitzpatrick skin type IV or V. Fitzpatrick type IV skin was 
observed in 10 (22.2%) subjects and Fitzpatrick type V skin was observed in 35 (77.78%) 
subjects in each arm. 
The clothing pattern of the subjects were categorised into minimal, moderate and 
maximal based on the amount of photo-exposed skin as explained in the methodology section. 
Since there were only 6 subjects in the 'maximal' category, they were clubbed with the 'moderate' 
Cases Controls
Outdoor 42.22% 42.22%
Indoor 57.78% 57.78%
0.00%
20.00%
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group during analysis. Among the cases there were 14 (31.11%) patients under the minimal 
photo-exposed category and 31 (68.89%) patients under the moderate category. Among the 
controls, there were 5 (11.11%) subjects under the minimal photo-exposed category and 40 
(88.89%) subjects under the moderate photo-exposed category (figure 7). This difference was 
found to be statistically significant (p = 0.02). Many psoriasis patients reported of wearing more 
covered type of clothing to avoid social stigma when they had lesions in the exposed parts. 
 
 
Figure 7: Type of clothing among the study subjects 
(Note: Minimal – less photo-exposed; Moderate – Moderately photo-exposed) 
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Moderate 31 40
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1.4. Sun-exposure and sunscreen usage 
The hours of sun-exposure per week among the cases ranged from 1 hour 35 minutes to 
56 hours and among the controls it ranged from 1 hour 10 minutes to 56 hours (p = 0.61). 
Eighteen (40%) cases had less than or equal to 30 minutes of average sun-exposure per day 
which was taken as inadequate sun-exposure and 20 (44.44%) controls had less than or equal to 
30 minutes of average sun-exposure per day.  
There were only four (4.44%) sunscreen users in the study group, all of whom belonged 
to the control arm. Among the sunscreen users, only one person (1%) used sunscreen regularly. 
Since the usage of sunscreen was very occasional in the other three subjects, further analysis was 
not done on this parameter. 
 Table 5 shows the baseline characteristics of the study population.  
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Table 5 – Baseline characteristics of the study population: 
Variable Cases 
n=45 
Controls 
n=45 
p-value 
Age (years) mean ± SD 41.62 ± 12.33 41.29 ± 12.40 0.90 
Sex [Frequency(%)] 
Male 
Female 
 
26 (57.78) 
19 (42.22) 
 
26 (57.78) 
19 (42.22) 
1.00 
Locality [Frequency(%)] 
Urban 
Semi-urban 
Rural 
 
1 (2.22) 
23 (51.11) 
21 (46.67) 
 
0 (0.00) 
29 (64.44) 
16 (35.56) 
0.31 
Occupation [Frequency(%)] 
Indoor 
Outdoor 
 
26 (57.78) 
19 (42.22) 
 
26 (57.78) 
19 (42.22) 
1.00 
Fitzpatrick Skin type [Frequency(%)] 
IV 
V 
 
10 (22.22) 
35 (77.78) 
 
10 (22.22) 
35 (77.78) 
1.00 
Clothing based on photoexposed skin.[Freq (%)] 
Minimal 
Moderate 
 
14 (31.11) 
31 (68.89) 
 
5 (11.11) 
40 (88.89) 
0.02 
Sun-exposure 
Avg. hours /week [median(min, max)] 
Avg hours/day < 30 min. [Freq (%)] 
 
7(1.35,56) 
18 (40) 
 
7(1.10,56) 
20 (44.44) 
 
0.61 
0.67 
 
SD – Standard deviation; Avg – Average; min – minimum; max – maximum; Freq - frequency 
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2. Behavioural patterns of study subjects 
2.1. Smoking 
There were a total of 9 (10%) smokers among the study subjects. The pack years ranged 
from 0.5 to 25. Among the 9 smokers, 6 belonged to the control group and 3 belonged to the 
cases. 6.67% of the patients and 13.33% of the controls were smokers (figure 8). There was no 
statistical difference (p = 0.29) with respect to smoking between both the groups. 
 
 
Figure 8 – Smoking among the study subjects 
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2.2. Alcohol consumption 
Among the cases, there were 7 (15.56%) subjects who consumed alcohol whereas among 
controls there were only 2 (4.44%) subjects who consumed alcohol. However, this difference 
was not statistically different (p = 0.079). In the control group, the average (minimal, maximal) 
monthly consumption of alcohol was 240 ml/month (120 ml, 360 ml) and that in cases was 545 
ml/month (20 ml, 2520 ml). 
2.3. Oral intake of vitamin D in the form of dairy products and fish 
 The oral vitamin D intake in the form of dairy products and fish was found to be very low 
in our study subjects. Among cases it ranged from 0 IU to 302 IU with a median of 16 IU. 
Among controls, it ranged from 2 IU to 101 IU with a median of 18 IU. Table 6 shows the 
behavioural patterns of the study population. 
 
Table 6 – Behavioural pattern of the study subjects: 
Variable Cases 
n=45 
Controls 
n=45 
p-value 
Smoking [Frequency (%)] 
Yes 
No 
 
3 (6.67) 
42 (93.33) 
 
6 (13.33) 
39 (36.67) 
0.29 
Alcohol intake [Frequency (%)] 
Yes 
No 
 
7 (15.56) 
38 (84.44) 
 
2 (4.44) 
43 (95.56) 
0.079 
 
Dietary vitamin D IU/day [Median(min, max)]  
 
16 (0, 302) 
 
18 (2, 101) 
 
0.62 
IU – International units; min – minimum; max - maximum 
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3. Known co-morbidities in the study group 
3.1. Diabetes Mellitus 
Ten (22.22%) cases and 7 (15.56%) controls were known diabetics on treatment. There 
was no significant difference (p = 0.419) in the distribution of known diabetics among the 
groups. Figure 9 shows the known co-morbidities among the study subjects. 
 
Figure 9: Known co-morbidities among the study group 
 
3.2. Hypertension 
 Seven (15.56%) cases and 1 (2.22%) control subject were known hypertensives. This 
distribution was found to be statistically significant (p = 0.026). 
Diabetes Hypertension Dyslipidemia
Cases 10 7 8
Controls 7 1 3
0
2
4
6
8
10
12
Fr
eq
u
en
cy
Known co-morbidities
58 
 
 
3.3. Dyslipidemia 
 Eight (17.78%) patients with psoriasis were known cases of dyslipidemia. But among 
controls there were only 3 (6.67%) subjects with dyslipidemia. However, this difference was not 
found to be statistically significant (p = 0.108). Table 7 shows the known co-morbidities among 
the study subjects. 
 
Table 7 – Known co-morbidities in the study population 
Variable Cases 
n=45 
Controls 
n=45 
p-value 
Diabetes Mellitus [Frequency (%)] 
Yes 
No 
 
10 (22.22) 
35 (77.78) 
 
7 (15.56) 
38 (84.44) 
0.419 
Hypertension [Frequency (%)] 
Yes 
No 
 
7 (15.56) 
38 (84.44) 
 
1 (2.22) 
44 (97.78) 
0.026 
Dyslipidemia [Frequency (%)] 
Yes 
No 
 
8 (17.78) 
37 (82.22) 
 
3 (6.67) 
42 (93.33) 
0.108 
 
 
  
59 
 
4. Metabolic syndrome related parameters 
4.1. Body Mass Index (BMI) and abdominal obesity 
Fifteen (33.33%) cases had a body mass index less than 25, whereas, among the controls, 
twenty nine (64.44%) had body mass index less than 25. Seventeen (37.78%) cases and 8 
(17.78%) controls were overweight (BMI between 25 and 30). Thirteen (28.89%) cases and 8 
controls (17.78%) were obese (BMI more than 30). The cases had a 4.75 times more risk of 
being overweight and 4.17 times more risk of being obese as compared to the controls. These 
variations in BMI were found to be statistically significant [p = 0.011 (overweight) and p = 0.028 
(obesity)]. The mean BMI among the cases was 27.12 ± 5.68 and that of the controls was 24.68 ± 
4.82 (p = 0.03). Figure 10 shows the categorisation of subjects based on BMI. 
 
Figure 10: Categorisation of the study groups based on body mass index 
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Abdominal obesity as defined (for Indian ethnicity) as waist circumference ≥ 90 cm in 
men and ≥ 80 cm in women was present in 31 (68.89%) cases and 19 (42.22%) controls (figure 
11). The patients with psoriasis were found to have 3.4 times higher risk for central obesity. This 
difference was found to be statistically significant (odds ratio 3.4, 95% confidence interval 1.25 
– 9.22, p = 0.016). The mean waist circumference among cases was 91.33 ± 13.18 cm and that of 
the controls was 84.49 ± 11.59 cm (p = 0.01). 
 
 
Figure 11: Central obesity among the study groups 
 
0
5
10
15
20
25
30
35
40
45
cases controls
Normal 14 26
Central obesity 31 19
Fr
eq
u
en
cy
Central obesity
61 
 
4.2. Raised fasting glucose level 
Nineteen (42.2%) cases and 15(33.4%) controls had either elevated fasting blood sugar 
level (≥ 100 g/dl) or were known diabetics on treatment. The patients with psoriasis had 1.6 
times higher risk of having raised fasting glucose level as compared to controls [Odds ratio 1.6, 
95% confidence interval (0.60 - 4.053)]. This difference was not found to be statistically 
significant (p = 0.35).  
4.3. Raised blood pressure 
 Twenty four (53.33%) cases and 7 (15.56%) controls had high blood pressure as 
suggested by the International Diabetes Federation which is systolic BP ≥ 130 mmHg or diastolic 
BP ≥85 mmHg or known hypertensives on treatment. This difference was found to be 
statistically significant (p = 0.002). Psoriatic patients were at a 9.5 times higher risk of having 
raised blood pressure as compared to the controls. (Confidence interval 2.1 – 40.8) 
 The mean systolic blood pressure was 132 ± 17 mmHg and 120 ± 13 mmHg among the 
cases and controls respectively (p < 0.001). The mean diastolic blood pressure was 85 ± 12 
mmHg and 78 ± 8 mmHg among the cases and controls respectively (p = 0.001). 
4.4. Raised triglycerides 
Fifteen (33.33%) cases and 12 (26.67%) controls had raised triglyceride levels (≥150 
mg/dl) or were already on treatment for dyslipidemia. This difference was not found to be 
statistically significant (p = 0.69). The mean triglyceride level was 139 ± 88 mg/dl and 115 ± 63 
mg/dl among the cases and controls respectively (p = 0.10). 
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4.5. Reduced HDL cholesterol 
Thirty (66.67%) of the cases and 27 (60%) of the controls had low HDL cholesterol level 
for their gender (< 40mg/dl for males and < 50mg/dl for females) or were already on treatment 
for dyslipidemia. This difference was not found to be statistically significant (p = 0.69). The 
mean HDL cholesterol level was 41 ± 9 mg/dl and 40 ± 10 mg/dl among the cases and controls 
respectively (p = 0.68). 
Figure 11 shows the distribution of metabolic syndrome related parameters among the 
subjects. 
 
Figure 12: Metabolic syndrome related parameters among the study groups 
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4.6. Metabolic syndrome 
 Alarmingly, 38 (42.22%) of our study subjects fulfilled the criteria for metabolic 
syndrome as put forth by the International Diabetes Federation. Twenty three (60.5%) of them 
were patients with psoriasis.  
 Twenty three (51.1%) of the 45 psoriatic patients and 15(33.33%) of the controls were 
found to have metabolic syndrome. Patients with psoriasis had a 2.3 times higher risk of 
metabolic syndrome as compared to the controls though it did not reach a level of statistical 
significance (p = 0.08). Table 8 shows the distribution of metabolic syndrome related parameters 
among the study subjects. 
Table 8 – Metabolic syndrome related parameters 
 
    Variable 
 [Frequency (%)] 
Cases 
n=45 
Controls 
n=45 
Odds ratio (95% 
Confidence interval) 
p-value 
Central obesity  31 (68.89) 
 
19(42.22) 
 
 
3.4(1.25 – 9.22) 0.02 
Hypertension  
 
24(53.33) 7 (15.56) 
 
 
9.5(2.1 – 40.8) 0.002 
Raised fasting glucose  
 
 
19 (42.2) 
 
15(33.4) 1.6(0.60 -  4.053) 0.35 
Hypertriglyceridemia  
 
 
15 (33.33) 12 (26.67) 1.38(0.56 – 3.41) 0.69 
Low HDL  
 
 
30 (66.67) 27 (60.0) 1.38(0.56 – 3.41) 0.69 
Metabolic syndrome  
 
 
23 (51.1) 15(33.33) 2.33(0.9 – 6.7) 0.08 
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5. Psoriasis patient profile 
5.1. Age at onset and duration of psoriasis vulgaris 
The age at onset of psoriasis in our study group ranged from 5 years to 60 years. The 
mean age at onset of the disease was 31.24 years. The duration of psoriasis at the time of 
recruitment into the study ranged from 3 months to 52 years. The mean duration of the disease 
was 10.38 years and the median was 6 years. 
Four (8.89%) patients had disease duration less than 1 year, 18 (40%) patients had 
disease duration ranging between 1 and 5years and 23(51.11%) patients had the disease for more 
than 5 years. The presence or absence of metabolic syndrome did not correlate (p = 0.74) with 
the disease duration as shown in the table 9. 
Table 9 – Correlation of disease duration with metabolic syndrome 
Disease duration Metabolic syndrome 
Present  
[Frequency (%)] 
Metabolic syndrome 
Absent  
[Frequency (%)] 
Total 
[Frequency (%)] 
<  1 year 2(9.09) 2(8.70) 4(8.89) 
1 to 5 years 10 (45.45) 8 (34.78) 18 (40) 
>  5 years 10(45.45) 13(56.32) 23(51.11) 
Total 22(100) 23(100) 45(100) 
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5.2. Type 1 and type 2 psoriasis 
Thirty three (73.33%) patients had early onset or type 1 psoriasis (onset before 40 years 
of age) and   12 (26.7%) patients had type 2 psoriasis. Three patients with type 1 disease and 2 
patients with type 2 disease had a positive family history. Among those with type 1 psoriasis, 14 
(42.42%) of them had metabolic syndrome and among those with type 2 psoriasis, 9 (75%) had 
metabolic syndrome (p = 0.053). Figure 13 shows the distribution of metabolic syndrome among 
patients with type 1 and type 2 psoriasis. 
 
Fig 13: Metabolic syndrome in type 1 and type 2 psoriasis 
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5.3. Seasonal variation 
 Of the 45 patients with psoriasis, 18 (40%) patients had winter exacerbation and 6 
(13.33%) patients had summer exacerbation. The remaining 21 (46.67%) patients had not 
observed any seasonal variation in the disease activity.  
5.4. Family history 
Five (11.11%) of the patients gave a positive family history of psoriasis. Three of these 
patients had type 1 psoriasis and two of them had type 2 psoriasis (p = 0.48). None of the control 
group subjects had family members having psoriasis. 
5.5. Social avoidance 
Fourteen (31.11%) patients avoided social activities due to the presence of the disease. 
All of them attributed the avoidance to social reasons. 
5.6. Disease severity measures - Body surface area involvement and PASI 
The body surface area (BSA) involvement among the patients ranged from 2% to 50%. 
Only one person (2.22%) had BSA involvement of less than 3%. Seven (15.56%) individuals had 
BSA involvement more than 10%. Thirty seven (82.22%) patients had BSA involvement 
between 3 and 10 per cent. 
Figure 14 shows the categorisation of disease severity based on BSA among the cases. 
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Figure 14: Body surface area involvement among the patients 
Majority of the patients, 35 (77.78%), had a PASI score less than 7. Seven (15.56%) 
patients’ PASI score ranged between 7 & 12 and 3 (6.67%) patients’ PASI score was above 12 
(figure 15). The mean PASI score was 5.27 ± 3.61. 
 
Figure 15: PASI score of the patients 
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 There was no correlation of PASI (r = -0.236, p = 0.12) as well as BSA involvement (r = 
-0.224, p = 0.14) with the BMI of the patients. 
5.7. Psoriatic arthritis 
Five (11.11%) of the 45 patients had psoriatic arthritis, out of which three had 
symmetrical polyarthritis and one each had asymmetric oligoarthritis and spondyloarthritis. All 
the 5 patients with arthropathy met the CASPAR criteria for psoriatic arthritis. The CRP level 
was elevated in 4 of them. The CRP level ranged from 1.48 to 49.7 mg/ l and the median value 
was 30 mg/l.  
5.8. Nail involvement and NAPSI 
 Two third (67.67%) of the 45 patients with psoriasis were noted to have psoriasis related 
nail changes, the commonest change being pits. The NAPSI score among our patients ranged 
from 0 to 37. 
6. Control patient profile 
 In the control arm, we had patients who presented with minor skin complaints like warts, 
fissures over the heels, superficial fungal infection etc. The frequency of each of the 
dermatological diagnosis is shown in table 10. The body surface area of involvement in all the 
cases were less than or equal to 5%. 
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Table 10 – Dermatological diagnosis among the control group 
Sl. No. Dermatological diagnosis Frequency (%) 
1 Superficial fungal infection 9 (20%) 
2 Viral wart 5 (11.11%) 
3 STI screening 1 (2.22%) 
4 Herpes labialis 1 (2.22%) 
5 Molluscum contagiosum 1 (2.22%) 
6 Pityriasis capitis 2 (4.44%) 
7 Fissures over heels 5 (11.11%) 
8 Erythrasma 4 (8.89%) 
9 Cherry angioma 2 (4.44%) 
10 Keloid 2 (4.44%) 
11 Zoons balanitis 1 (2.22%) 
12 Acne grade 1 2 (4.44%) 
13 Androgenetic alopecia 1 (2.22%) 
14 Post herpetic neuralgia 2 (4.44%) 
15 Post inflammatory hyperpigmentation 3 (6.67%) 
16 Black hairy tongue 1 (2.22%) 
17 Pigmented purpuric dermatoses 2 (4.44%) 
18 Corn 1 (2.22%) 
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7. Vitamin D levels 
7.1. Vitamin D status of the study population 
Twenty eight (62.22%) cases and 20 (44.44%) controls had vitamin D deficiency 
(≤20ng/ml). The overall prevalence of vitamin D deficiency (≤ 20ng/ml) among the subjects was 
53.33%.  Though there was a 17.78% difference in the prevalence of vitamin D deficiency 
between the cases and control, it was not statistically significant (p=0.096). Only 8 (17.78%) 
subjects in each arm had normal vitamin D level (≥ 30 ng/ml). Nine (20%) cases and 17 
(37.78%) controls had vitamin D insufficiency (20 to 30 ng/ml) (figure 16). Therefore the 
prevalence of vitamin D insufficiency / deficiency (≤ 30 ng/dl) in our study population was 
82.22%. 
 
Figure 16: Vitamin D status of cases and controls 
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Table 11: Vitamin D status of the study population 
 
Variable Normal  Insufficient  Deficient  
[Frequency (%)] 
Cases  
Controls  
 
8(17.78) 
8(17.78) 
 
9 (20) 
17(37.78) 
 
28 (62.22) 
20 (44.44) 
Odds ratio (95% 
confidence interval) 
p - value 
 
----- 
---- 
 
2.06( 0.82 – 5.21) 
0.09 
 
0.38 (0.14 – 1.08) 
0.06 
 
The mean vitamin D level (ng/ml) among the cases was 21.54 ± 9.41 and that of the 
controls was 21.24 ± 10.97 (p = 0.64). The cases and controls were further categorised into two 
groups (table 12) based on the presence (≤ 20 ng/ml) or absence of vitamin D deficiency (> 20 
ng/ml). 
Table 12: Vitamin D deficiency of the study population 
Variable Deficiency (≤ 20ng/ml) No deficiency (> 20 ng/ml) 
Cases [Frequency (%)] 28 (62.22) 17 (37.78) 
Controls [Frequency (%)] 20 (44.44) 25 (55.56) 
Odds ratio – 2.14; 95% Confidence interval - (0.87 – 5.26); p – value = 0.096 
The psoriatic patients had a 2.14 times higher risk of vitamin D deficiency as compared 
to our controls.  However this difference was not found to be statistically significant (odds ratio 
2.14, 95% confidence interval 0.87 – 5.26, p = 0.096). 
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7.2 Correlation of vitamin D with baseline characteristics of the study subjects 
7.2a Correlation of vitamin D with gender and age 
Thirty one (60%) of the 52 men and 17 (45%) of the 38 women enrolled in this study 
were found to have vitamin D deficiency. There was no statistically significant difference 
between the prevalence of vitamin D deficiency among men and women (p = 0.1623). Table 13 
shows the correlation of vitamin D deficiency with gender of the study subjects. 
 There was no significant correlation of vitamin D level with the age of the study subjects 
(r = 0.169, p = 0.11). 
Table 13 - Correlation of vitamin D status with gender 
Variable Male  
[Frequency (%)] 
Female  
[Frequency (%)] 
p value 
Vitamin D deficiency 31 (60) 17 (45) 0.1623 
No vitamin D deficiency 21 (40) 21 (55) 
 
7.2b Correlation of vitamin D level with locality and skin type among the study subjects 
 The mean serum vitamin D level of the study subjects from semi-urban set up was 16.44± 
1.63 ng/dl and that of those from rural set up was 23.57± 1.48 ng/ dl. This difference was 
statistically significant (p = 0.0004). 
The mean serum vitamin D level of the subjects with type IV skin was 18.18 ± 8.88 
ng/ml and that of subjects with type V skin was 22.30 ± 10.38 ng/ ml and the difference was not 
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statistically significant. Table 14 shows the correlation of vitamin D level with locality and skin 
type of the study subjects. 
Table 14: Correlation of vitamin D level with locality and skin type 
 
Variable Mean vitamin D level (ng/dl) p - value 
Locality 
Semi-urban 
Rural 
 
16.44± 1.63 
23.57± 1.48 
0.0004 
Skin type 
Type IV 
Type V 
 
18.18 ± 8.88 
22.30 ± 10.38 
0.1162 
 
 
7.2c Correlation of vitamin D status with type of occupation and sun-exposure among the 
study subjects 
 Among the study subjects, there were 38 (42.22%) outdoor workers and 52 (57.78%) 
indoor workers. Fifteen (39.47%) of the outdoor workers and 33(63.5%) of the indoor workers 
were found to have vitamin D deficiency. A positive correlation of indoor occupation with 
vitamin D deficiency was noted and it was found to be statistically significant (p = 0.024). 
Figure 17 shows the correlation of vitamin D status with the type of occupation. 
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Figure 17: Correlation of vitamin D status with type of occupation 
 Thirty two (32.56%) of the 90 study subjects, reported average sun-exposure less than 30 
minutes per day. Among them, 22(68.8%) were found to have vitamin D deficiency. Among the 
58 subjects with average sun-exposure more than 30 minutes per day, vitamin D deficiency was 
noted in 26 (44.83) subjects (table 15). This difference was found to be statistically significant (p 
= 0.03). 
Table 15 – Correlation of vitamin D level with occupation and sun-exposure 
Variable[Frequency (%)] Vitamin D ≤ 20ng/dl Vitamin D >20ng/dl p - value 
Occupation 
Indoor  
Outdoor  
 
33(63.5) 
15 (39.47) 
 
19 (36.5) 
23 (60.53) 
 
0.02 
Sun-exposure 
Inadequate  
Adequate  
 
22(68.75) 
26(44.83) 
 
10 (31.25) 
32(55.17) 
 
0.03 
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7.2d Correlation of vitamin D level with smoking among the study subjects 
 There was no statistical difference (p = 0.07) between the mean serum vitamin D level of 
smokers (16.08± 7.11 ng/ml) and non-smokers (21.98 ± 10.31 ng/ml).  
Since there were only 9 subjects who consumed alcohol out of which 6 of them 
consumed alcohol only occasionally, it was not analysed. 
7.3 Correlation of vitamin D level with type of clothing and sun-exposure among cases 
 The mean serum vitamin D level was only 14.48 ± 6 ng/ml among those who wore 
covered type of clothing whereas the corresponding level among those whose clothing allowed 
more of photo-exposure was 23.23 ± 10.28 ng/dl (p = 0.0001).  
Among the 14 psoriatic patients who wore covered type of clothing, 12 (85.7%) of them 
had vitamin D deficiency. Among the 31 psoriatic patients whose clothing allowed more of 
photo-exposure, 16 (51.6%) of them had vitamin D deficiency and this difference was found to 
be statistically significant (p = 0.02). Figure 18 shows the correlation of the type of clothing with 
the vitamin D status of the cases. 
The average duration of sun-exposure per day showed a positive correlation with the 
serum level of vitamin D and it was found to be significant (r = 0.5013, p = 0.0005). 
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Figure 18: Clothing and vitamin D deficiency among cases 
 
7.4. Correlation of type 1 and type 2 psoriasis with vitamin D level 
The mean vitamin D level was lower among patients with type 1 psoriasis (19.56 ± 
9.8ng/ml) as compared to those with type 2 psoriasis (25.86 ± 12.99). However the difference 
was not statistically significant (p = 0.15). 
7.5. Correlation of vitamin D status with arthritis and nail involvement among the psoriatic 
patients  
 Of the 5 patients with arthritis, 2 of them had vitamin D deficiency. Since the number of 
patients with arthritis was low, it could not be analysed further. Nineteen of the 30 patients with 
nail involvement (63.33%) had vitamin D deficiency which was not statistically significant (p = 
0.50). 
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7.6. Correlation of vitamin D level with disease duration, BSA involvement and PASI 
among patients 
The disease duration showed a negative correlation with vitamin D level which showed 
tendency towards statistical significance (r = -0.2978, p = 0.047). So with an increase in disease 
duration there is a tendency towards decrease in vitamin D level. 
 The BSA involvement did not show significant correlation with vitamin D level (r = 
0.2014, p = 0.18). Similarly PASI also did not show any significant correlation with vitamin D 
levels (r = 0.2598, p = 0.08). Table 16 shows the correlation of vitamin D level with sun- 
exposure, disease duration and disease severity. 
Table 16: Correlation of vitamin D with sun-exposure, disease duration, BSA and PASI 
Variable Correlation with vitamin D 
level   r 
p – value 
Average sun-exposure / day 0.5013 0.0005 
Disease duration -0.2978 0.047 
BSA involvement 0.2014 0.18 
PASI 0.2598 0.08 
 
7.6. Correlation of vitamin D level with metabolic syndrome related parameters among the 
psoriatic patients 
The BMI (r = -0.300, p = 0.045) and fasting blood sugar (r = -0.319, p = 0.037) showed a 
negative correlation with serum vitamin D level. With the increase in BMI and fasting blood 
78 
 
sugar, there was decrease in the serum vitamin D level. The HDL level of the cases showed a 
positive correlation with vitamin D level (r = 0.34, p =0.026). 
 The waist circumference (r = -0. 257, p = 0.09), systolic (r = -0.209, p = 0.17) and 
diastolic blood pressure (r = -0.134, p = 0.38) as well as triglyceride levels (r = -0.043, p = 0.78) 
did not show any significant correlation with the vitamin D level. 
Table 17 shows the correlation of vitamin D level with BMI, central obesity, blood 
pressure, fasting blood sugar, HDL and triglycerides. 
Table 17: Correlation of vitamin D level with metabolic syndrome related parameters 
Variable Correlation with vitamin D level  r p - value 
Body mass index -0.300 0.045 
Fasting blood sugar -0.319 0.037 
Waist circumference -0. 257 0.09 
Systolic blood pressure -0.209 0.17 
Diastolic blood pressure -0.134 0.38 
HDL 0.340 0.026 
Triglycerides -0.043 0.78 
 
 
79 
 
The mean serum vitamin D level of the cases with metabolic syndrome was 24.53 ± 
12.79 ng/ml whereas the mean serum level of the psoriatic patients without metabolic syndrome 
was 18.09 ± 7.96 ng/ ml. However this difference was not found to be significant (p = 0.096). 
 
7.8. Multivariate analysis with logistic regression of vitamin D level with psoriasis, clothing, 
skin type, locality, occupation, sun-exposure and BMI  
 A logistic regression analysis of vitamin D level with psoriasis, clothing, skin type, 
locality, occupation, duration of sun-exposure per day and BMI was performed. The results are 
summarised in table 18. The presence of psoriasis was not associated with changes in vitamin D 
level after adjusting for clothing, skin type, locality, occupation, sun-exposure and BMI.  
When compared to wearing more covered type of clothing, more photo-exposed type of 
clothing was shown to increase the serum vitamin D level by 47% after adjusting for skin type, 
locality, occupation, duration of sun-exposure and BMI.  
When compared to residing in a semi-urban locality, residing in a rural locality was 
shown to increase the serum vitamin D level by 24% after adjusting for clothing, occupation, 
duration of sun-exposure and BMI. 
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Table 18 -Multivariate analysis with logistic regression of vitamin D level with psoriasis, 
clothing, skin type, sun-exposure, BMI, locality and occupation 
Variable Coefficient β Standard error p - value 95% confidence interval  β back 
transformed 
Cases (vs. controls) 0.0368638   0.0979007     0.707     -0.1578919  to 0.2316195 4% 
Clothing-Moderate  
photo-exposed (vs. 
minimal) 
0.3886164 0.1200021 0.002     0.149894  to  0.6273388 47% 
Skin type V(vs. type 
IV) 
0.0078483   0.1166093      0.947       -0.2241249 to 0.2398214 0.8% 
Duration of sun-
exposure per day  
0.0175861   0.0282195     0.535      -0.0385516 to 0.0737238 2% 
BMI 
 
-0.0085946   0.0092873 0.357     -0.0270699 to 0.0098808 0.9% 
Rural (vs. semi- 
urban) 
0.2174402   0.1009797 0.034     0.0165594     0.418321 24% 
Indoor occupation 
(vs. outdoor) 
-0.0778305  -0.0778305 
  
0.565   -0.3455057  to  0.1898447 
 
7% 
 
 
Note - Skewed variables were log transformed and back-transformed, and interpreted as 
percentage change. R-squared = 28.16% 
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Discussion 
 
Vitamin D is now recognised as a hormone that has pleiotropic actions on various cells 
and tissues in the body.(63) Recent research has implicated vitamin D deficiency with a number 
of chronic conditions, including autoimmune disorders such as multiple sclerosis, lupus 
erythematosus and dermopathies such as psoriasis.(86) The recent discovery of the role of 
vitamin D in modulating the immune system especially the Type 1 helper T cell (Th1) pathway 
shows its potential in treating Th1 related inflammatory diseases.  Psoriasis is a Th1 immune 
mediated genetically determined common disorder affecting the skin, nails, joints and it has 
various systemic associations.(25) There are recent studies that show vitamin D deficiency in 
psoriasis patients more than in controls.(10–13) 
 Psoriasis is also a systemic disease centered on inflammation and involvement of 
cytokines of the Th1 pathway. Metabolic syndrome also involves a proinflammatory state and 
there is increased prevalence of metabolic syndrome in psoriasis. Fu and Vender  have proposed 
the idea of the potential use of oral vitamin D to treat psoriasis and metabolic syndrome 
concurrently.(87) 
There were no known published Indian studies on the relationship between vitamin D 
deficiency and psoriasis at the time of commencement of this study, which prompted us to 
undertake this prospective observational case-control study. 
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1. Demographic profile 
In our study, the mean age of the cases was 41.62 years (± 37.92) and that of the control 
group was 41.29 years (± 37.56). This was almost the same as that reported by Gutte et al. from 
Mumbai.(17) When compared with the studies in western countries, the mean age was around 2 
to 3 years lower than that reported in the studies from Spain(11,12) and Egypt(39) and 10 years 
lower than that reported from Italy.(13) The male : female ratio in our study was 1.4 : 1 which 
was consistent with the fact that there is male preponderance of the disease.(25)  
There was no correlation of vitamin D level with age or gender among our study group. 
Orgaz-Molina et al., in their study found a negative correlation of vitamin D level with age of 
their patients ( r = –0.477, p = 0.001).(11) Bentli et al., in their study reported female gender to 
be an independent predictor of vitamin D deficiency.(88) Johnson et al., in their study on the 
impact of gender on vitamin D status in morbidly obese individuals, noted a higher rate of 
vitamin D deficiency in men as compared to women (56% versus 47%; p <0.001).(89) In our 
study higher proportion of men (60%) had vitamin D deficiency as compared to women (45%) 
which however did not reach a level of statistical significance (p = 0.1623). 
 Majority of our study subjects (57.78%) were from semi-urban areas. There was only one 
individual from an urban set up (1.11%) and 41.11% were from rural set up. The study from 
Spain by Orgaz- Molina et al was in a metropolitan set up (11) and the others studies on psoriasis 
and vitamin D had not specified the locality. Most of our study subjects (57.78%) were engaged 
in indoor occupation. With the rapid urbanization there are lesser number of people engaged in 
outdoor occupations like agriculture.(90) This results in less of sun-exposure which is essential 
for the cutaneous synthesis of vitamin D in the body. 
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 Our study subjects either had Fitzpatrick skin type IV or V, with the type V skin being 
more common (77.78%). Melanin is an effective natural sunscreen. Because of the effective 
absorption of UVB photons by melanin, dark-skinned individuals require longer duration of 
exposure to sunlight to make the same amount of vitamin D3, when compared with light-skinned 
individuals. It has been shown that a young adult with skin type III who was exposed to 1 
minimal erythema dose (MED) of 54 mJ/cm2 exhibit a 50-fold increase in serum vitamin D3 
within 8 hours. An adult of the same age with skin type V when exposed to 54 mJ /cm2 did not 
show any significant rise in circulating concentrations of vitamin D3. He required 5-10 times the 
exposure and exhibited only a 30-fold increase in the blood concentration of vitamin D3.(91) The 
skin type was not documented in the study by Gutte et al.(17) Among the other reported studies, 
the study by Gisondi et al.(13) included white-skinned (Fitzpatrick type not specified). In a study 
by Orgaz -Molina et al.,(11) they included all the 6 skin types with fairly equal numbers with 
type ( I to III) and (IV to V) and another study by the same authors (12) included those with skin 
types II to IV. The study by Hesham Abd El-Moaty Zaher et al.(39) from Egypt included skin 
types III to V. However the data on correlation of vitamin D level with the skin type were not 
available for comparison with the results in our study. 
Table 19 shows comparison of demographic profile of study subjects as reported in studies on 
vitamin D deficiency and psoriasis. 
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Table 19 – Comparison of demographic profile of study subjects on vitamin D deficiency 
and psoriasis 
Parameter Our study Orgaz-Molina 
et al.(11) 
Study 1 
Orgaz Molina 
et. al (12) 
Study 2 
Gisondi et 
al(13)  
Hesham Abd 
El-Moaty 
Zaher  et al(39) 
Gutte et al.(17) 
Country India Spain Spain Italy Egypt India 
(Mumbai) 
Study period December  
2013- August  
2014 
July – August 
2011 
 
May – June 
2011 
 
December 
2000 - 
December 
2010 
Published in 
November 
2013 
Published in 
June 2014 
Study duration 9 months 1.5 months 1 month 1year NA NA 
Study design Case- control Case- control Case -control Case- control Case- control Case- control 
Subjects 
(Number in 
each arm) 
CPP and minor 
dermatological 
ailments  
(45,45) 
CPP (no 
arthritis) & 
minor 
dermatological 
(46,46) 
CPP and minor 
dermatological 
ailments 
(43,43) 
CPP & 
Rheumatoid 
arthritis and 
healthy 
controls 
(145,112,141) 
CPP & healthy 
controls 
(48,40) 
Psoriasis (type 
not specified) 
and healthy 
controls 
 (50, 50) 
Matching Age & sex Age & sex Age & sex Not done Age, sex,  
phototype &  
socio 
economic 
status 
Age & sex 
Age-years  
(mean±SD) 
Cases 
controls 
 
 
41.62±12.33 
41.2 ± 12.40 
 
 
45.57±9.96 
45.89± 10.06 
 
 
44.33± 8.71 
43.95±11.3 
 
 
51.9 ± 13.3 
51.4 ± 7.0 
 
 
43.88±15.157 
42.28 ± 13.602 
 
 
41  
42  
M:F 1.4:1 1.3:1 1.9:1 1.7:1 1.3:1 1.08:1 
Locality 
categories 
Urban, semi- 
urban & rural 
NA Metropolitan  NA NA NA 
Fitzpatrick 
type 
IV & V I to VI II, III, IV White- skinned III, IV, V NA 
 
NA – Data not available; SD – Standard Deviation; CPP – Chronic Plaque Psoriasis 
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2. Comparison of data on sun-exposure 
The hours of sun-exposure per week among the cases ranged from 1 hour 35 minutes to 
56 hours and among the controls it ranged from 1 hour 10 minutes to 56 hours( p = 0.61). The 
average hour of sun-exposure per week among the cases was 15 hours and the same among the 
controls was 17 hours. This was much less as compared to the studies (>24 hours/week) reported 
from Spain,(11,12) despite India being a land of sunshine. The other Indian study did not have 
the data on sun-exposure.(17) 
Gisondi et al.(13), in their study had categorised the subjects into those with an average 
sun-exposure per day less than 30 minutes and more than 30 minutes. Seventy seven per cent of 
their cases and 76% of their controls had an average sun-exposure per day less than 30 minutes. 
On comparing with that data, we had 40% cases having less than 30 minutes of average sun- 
exposure per day and 44% controls having less than 30 minutes of average sun-exposure per day. 
Their control group, despite 76% of them with less sun-exposure had a mean serum vitamin D 
level of 37.1 ± 27.6 ng/ml. The corresponding level in our control group was only 21.24 ± 
10.97ng/ml. The Fitzpatrick skin type of the study population could possibly be one of the 
reasons for this observation. 
There is a wide variation in the sun-exposure due to latitude, time of day, season, 
atmospheric components, sunscreen use, clothing and skin pigmentation.(63) It has been noted 
that there is greater variability in personal ultraviolet (UV) light exposure resulting from personal 
behaviour like avoidance of sun-exposure, clothing, sunscreen usage than from ambient UV light 
exposure.(92) The reported studies on vitamin D and psoriasis(11–13,39) have taken into 
account the latitude, the duration of sun-exposure, seasonal variations and to a certain extent skin 
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pigmentation. However the data on sunscreen usage and clothing among the study subjects was 
not available in these reports. 
Studies show that a sunscreen having a sun protection factor (SPF) of 8 reduces the 
capacity of the skin to produce vitamin D by 95% if applied in the ideal way.(91) However there 
are studies showing that in most individuals the sunscreen usage is far from what is ideal, 
making it an unlikely factor to majorly contribute to the vitamin D status of individuals.(92) 
There were only four (4.44%) sunscreen users in our study group, all of whom belonged to the 
control arm. Out of that only one person (1%) used it regularly. Hence further analysis was not 
possible on this parameter. 
Clothing  is one of the major factor affecting the cutaneous absorption of vitamin D. 
Dense woven fabrics significantly reduce the transmission of UV radiation than the loose-knit 
ones.  A study looking at the effect of white and black fabrics on UV exposure found that black 
wool decreased UVB irradiation by 98.6% whereas white cotton reduced it by 47.7%. However, 
after 40 minutes of simulated sunlight or whole body irradiation in volunteers with up to 6 MEDs 
of UV radiation both the fabrics suppressed vitamin D synthesis completely.(63) 
In our study we had categorised the type of clothing based on the area of skin that was 
photo-exposed into minimal, moderate and maximal as explained in detail in the methodology. 
Since there were only 6 subjects in the 'maximal' category, they were clubbed with the 'moderate' 
group during analysis. Among the cases there were 31.11% patients under the minimal photo-
exposed category and 68.89% patients under the moderate category. Among the controls, there 
were 11.11% subjects under the minimal photo-exposed category and 88.89% subjects under the 
moderate photo-exposed category. This difference was found to be statistically significant. Many 
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psoriasis patients reported of wearing more covered type of clothing to avoid social stigma when 
they had lesions in the exposed parts.  Thirty one per cent of our cases avoided social activities 
due to the presence of the disease. 
Table 20 - Comparison of data on sun-exposure in various studies on vitamin D and 
psoriasis 
Parameter Present 
study 
Orgaz Molina 
et al (11) 
Study 1 
Orgaz Molina 
et. al (12) 
Study 2 
Gisondi et 
al(13)  
Hesham Abd 
El-Moaty 
Zaher  et al(39) 
Gutte et al.(17) 
Country India Spain Spain Italy Egypt India 
Year December  
2013- 
August  
2014 
July – August 
2011 
May – June 
2011 
December 
2000 - 
December 
2010 
Published in 
November 
2013 
Published in 
June 2014 
Sun-exposure 
(Hours/ week) 
cases 
controls 
Median 
 ( range) 
7(1.35, 56) 
7( 1.10,56) 
Mean (SD) 
 
25.98 ± 16.42 
23.87 ± 17.14 
Mean (SD) 
 
25.99 ± 18.78 
28.22 ± 20.33 
NA NA NA 
Sun-exp < 30 min. 
/ day [Freq (%)] 
cases 
controls 
 
 
18(40%) 
20(44.4) 
 
 
NA 
 
 
NA 
 
 
112(77.2) 
107(75.9) 
Infrequent sun- 
exposure 
11 (22.9) 
 7 (17.5) 
 
 
NA 
 
NA – Data not available; SD – Standard Deviation; Sun-exp – Sun-exposure; Freq - Frequency 
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The mean serum vitamin D level was only 14.48 ± 6 ng/ml among those who wore 
covered type of clothing whereas the corresponding level among those whose clothing allowed 
more of photo-exposure was 23.23 ± 10.28 ng/dl. (p = 0.0001). Since the other studies on 
vitamin D and psoriasis did not have this data, we could not compare our observation. 
Considering the small sample size, probably further larger studies are needed to establish the role 
of type of clothing in the vitamin D status of the patients with psoriasis. 
3. Dietary intake of food rich in vitamin D 
Vitamin D intake in diet is very low in India because of the very low consumption of 
vitamin D rich foods, low use of supplements and absence of fortification .(93) Therefore most 
of the Indian studies on vitamin D do not provide the data on oral vitamin day intake as it has 
been found to be negligible.(93) We collected the data on oral vitamin D intake in the form of 
dairy products and fish. Among cases it ranged from 0 IU to 302 IU with a median of 16 IU. 
Among controls, it ranged from 2 IU to 101 IU with a median of 18 IU. In the study, by Orgaz- 
Molina et al.,(11) the mean oral vitamin D intake among the cases was 188.72 ± 136.83 IU and 
that among the controls was 172.92 ± 102.18 IU. 
 The Food and Nutrition Board recommended dietary allowance (RDA) for infants below 
one year of age is 400 IU daily. Between 1 and 70 years of age, the RDA is 600 IU and for 
elderly over 70 years of age, it increases to 800 IU(72). However it has been shown that > 90% 
of vitamin D synthesis depends on ultraviolet exposure (cutaneous synthesis). 
4.  Psoriasis patient profile 
The age at onset of psoriasis in our study group ranged from 5 years to 60 years. The 
duration of psoriasis at the time of recruitment into the study ranged from 3 months to 52 years. 
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And the mean duration of the disease was 10.38 years and the median was 6 years. In the study 
by Orgaz- Molina et al.,(11) the mean duration of disease was 18.58 ± 11.81 years, which was 
higher than in our study group. 
 A significant proportion of our patients (73.33%) had type 1 or early onset psoriasis, 
despite having excluded all psoriatic patients aged less than 18 years in the study. In our study, 
early onset psoriasis did not correlate with the positive family history of psoriasis. Indian studies 
report a lower familial incidence of the disease.  Bedi et al (94) reported positive family history 
of psoriasis in 14% of their patients, while Kaur (95) et al reported family history in only 2% of 
their patients. Eleven per cent patients gave a positive family history of psoriasis in our study. 
Among our patients, 46.67% had not observed any seasonal variation in the disease 
activity. Forty per cent had winter exacerbation and 13.33% had summer exacerbation. Bedi et al 
from India found that 72% of patients had significant seasonal variations, of which 30% felt 
worse in winter, 16% in monsoon and 4% in summer while the rest (28%) had persisting lesions 
all through the year, with erratic fluctuations not attributable to any particular season.(94) 
Eleven per cent of our patients had psoriatic arthritis. In a recent Indian study on the 
prevalence and clinical patterns of psoriatic arthritis by Kumar et al., 8.7% of the patients with 
psoriasis had psoriatic arthritis, the commonest being symmetric polyarthritis, which is similar to 
our data.(96) In the study correlating vitamin D status and psoriasis by Orgaz- Molina et al., the 
prevalence of psoriatic arthritis was 7%. In the study by Gisondi et al., it was much higher 
(40.7%). In both the studies, there was no correlation between the presence of arthritis and 
vitamin D deficiency.(12,13)  
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Two third of our patients with psoriasis were noted to have psoriasis related nail changes, 
the commonest change being pits and the data was comparable with the other Indian studies.(25) 
The NAPSI score among our patients ranged from 0 to 37. Orgaz – Molina et al. reported nail 
involvement in only 14% of their cases. There was no correlation with vitamin D deficiency and 
nail involvement as in our study.(12) 
5.  Disease severity measures (PASI and BSA involvement) 
The PASI score among our cases ranged from 0.9 to 15.6. Majority (78%) of the patients 
had a PASI score less than 7. The mean PASI score was 5.27 ± 3.61 which was almost similar to 
the PASI score reported in the study by Orgaz – Molina et al. where it was 4.28 ± 4.38.(11) The 
reason for the low PASI score could be because of excluding all the cases on systemic therapy 
and phototherapy as per the inclusion criteria. 
The BSA involvement among our patients ranged from 2% to 50%.  Sixteen per cent 
patients had BSA involvement more than 10%. The mean BSA involvement in our study was 
8.51 ± 9.26 %, which was marginally above the BSA involvement reported by Orgaz- Molina et 
al. which was 5.10 ± 7.08%.(11) The disease severity measures were not documented in the 
other Indian study.(17) 
6. Metabolic syndrome related parameters 
Metabolic syndrome is a cluster of the most important risk factors for heart attack 
namely,  abdominal obesity, high cholesterol, diabetes & pre-diabetes, and high blood 
pressure.(44) It has a prevalence of 20 to 25% of the adult population. It is also referred to as 
‘Syndrome X’, ‘Deadly Quartet’ or the ‘Insulin Resistance Syndrome’.  
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Metabolic syndrome shares some common immunological mechanisms with psoriasis. 
 Adipocytokines secreted by the intra-abdominal fat cells affect glucose 
metabolism and promote inflammation. This causes elevated levels of 
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and plasminogen 
activator inhibitor type1. These levels have been found to be elevated in psoriasis 
as well. 
  Leptin, a hormone secreted by adipocytes plays a pro inflammatory role in 
regulating cytokine expression which modulates the Type 1 and Type 2 helper 
cells. Hyperleptinemia is found to be associated with the development of 
metabolic syndrome as well as with psoriasis.(45)  
 Adiponectin, produced by adipocytes suppresses the production of TNF-α, IL-6 
and INF-α. It has anti atherogenic effects and improves insulin sensitivity. 
Visceral obesity causes hypoadiponectinemia, which in turn increases the 
proinflammatory cytokines favoring the development of psoriasis as well as 
atherosclerosis. 
  Osteopontin, an inflammatory glycoprotein which exerts a Th1 cytokine effect is 
thought to play a role in atherogenesis. Psoriasis is found to be a risk for elevated 
levels of osteopontin.(46) 
 Hyperinsulinemia in metabolic syndrome can possibly promote susceptibility to 
or severity of psoriasis by facilitating chronic inflammation and angiogenesis. 
 PSORS2-4, CDKAL1, and ApoE4 implicated in the shared genetic susceptibility 
to both metabolic syndrome  and psoriasis.(15) 
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The overall prevalence of metabolic syndrome in our study population was 42%. The 
mean BMI of our cases was 27.12 ± 5.68 and it was significantly more than that of our controls 
which was 24.68 ± 4.82. (p = 0.03) These values were similar to the results of Gisondi et al., 
where the mean BMI of cases and controls was 26.6 ± 4.1 and 24.0 ± 3.7 respectively (p = 
0.001).(13) In the study by Orgaz – Molina et al., there was a tendency towards significance, that 
is BMI  of 29.68 ± 7.07 among cases and 27.17 ± 4.45 among controls ( p = 0.05).(12) The 
metabolic syndrome related parameters were not available in the Indian study.(17) 
 Central obesity was observed in 69% of the cases and 42% of the controls ( p = 0.02).In a 
recent south Indian study, 45 % cases and 39% controls had central obesity (p = 0.05).(97) The 
mean waist circumference among our cases was 91.33 ± 13.18 cm and that of the controls was 
84.49 ± 11.59 cm ( p  = 0.01). In the study by Orgaz - Molina et al., there was no significant 
difference between the waist circumference of the cases (97.57 ± 10.74 cm) and controls (94.58 
± 11.75cm).(11)  
 In our study, the mean systolic blood pressure as well as the diastolic blood pressure 
among the cases was significantly higher than that in the controls. It was 132 ± 17/85 ± 12 
mmHg among cases and 120 ± 13 /78± 8 mmHg among the controls. (Systolic BP -  p < 0.001, 
Diastolic BP -  p = 0.001). However in the studies by Orgaz- Molina et al.(11) and Gisondi et 
al.(13) there was no significant difference in the blood pressure between the cases and controls. 
Armstrong et al.(98) in a systematic review and meta-analysis of observational studies on the 
association between psoriasis and hypertension, noted an odds ratio of 1.58 (95% confidence 
interval 1.42-1.76) for hypertension among patients with psoriasis compared to controls.  
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 In contrast to the observation by Orgaz – Molina et al., there was no statistical difference 
between the cases and controls with respect to fasting blood sugar values and triglycerides in our 
study. In concordance with their study, there was no significant difference in the HDL levels 
between their cases and controls. However the mean HDL level was higher than that observed in 
our study. Our cases and controls had a mean HDL level of 40.71 ± 9.13 mg/dl and 39.85 ± 
10.07mg/ dl respectively whereas their cases and controls had a mean HDL level of 52.52 ± 
14.38 mg/dl and 54.54 ± 13.36 mg/dl respectively.(11)  
 Fifty one percent of our cases and 33% of our controls had metabolic syndrome. 
However it was not statistically significant (p = 0.08). Orgaz – Molina et al. had 30% cases and 
17% controls having metabolic syndrome (p = 0.143).(11) The higher prevalence of metabolic 
syndrome was in concordance with the study by Madanagopalane et al. in south India where 
44% of the patients with psoriasis were noted to have metabolic syndrome.(45) 
The link between psoriasis and metabolic syndrome has clinical implications as it relates 
to the safety and efficacy of commonly used systemic medications. For example, more 
aggressive liver monitoring guidelines are recommended for psoriatic patients with components 
of the metabolic syndrome like obesity and diabetes who are taking methotrexate.(99) Of note, 
patients with psoriasis also have an increased frequency of non-alcoholic fatty liver disease.(100) 
Increasing BMI is known to be associated with a reduction in psoriasis treatment efficacy, 
especially with the non-weight based biologic therapies.(101) Emerging data suggest that 
systemic treatment of psoriasis may be associated with an improvement in the metabolic risk 
biomarkers.(102) Therefore an early screening and intervention including life style modifications 
in patients with psoriasis would have an impact on the patients’ overall health. 
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7. Vitamin D 
Vitamin D3 is now known to act on the vitamin D receptor (VDR) to regulate 
keratinocyte growth and differentiation. It also influences the immune functions of dendritic cells 
and T lymphocytes, which are the key players in the pathogenesis of psoriasis. Hence it is 
suggested that low levels of vitamin D may have important implications in the pathogenesis of 
psoriasis.(19) Table 21 compares the prevalence of vitamin D deficiency in our study with the 
other studies on vitamin D and psoriasis. 
Table 21 – Prevalence of vitamin D deficiency in studies on vitamin D and psoriasis 
 
The overall prevalence of vitamin D deficiency (≤ 20ng/ml) in our study subjects was 
53.33%. Gutte et al, from India reported a prevalence of 80% in their study.(17) The two studies 
reported from Spain by Orgaz – Molina et al. showed a much lesser prevalence among their 
subjects (10.98% and 17.4%).(11,12) Hesham Abd El-Moaty Zaher et al. from Egypt (39) also 
reported vitamin D deficiency in only 13.64% of their subjects. The Italian study by Gisondi et al 
had a slightly higher prevalence (41.46%).(13) In the Indian scenario, a very high prevalence of 
Parameter Present 
study 
Orgaz-
Molina et 
al. (11) 
Study 1 
Orgaz- 
Molina et. 
al (12) 
Study 2 
Gisondi et 
al.(13)  
Hesham 
Abd El-
Moaty 
Zaher  et 
al.(39) 
Gutte et 
al.(17) 
Country India Spain Spain Italy Egypt India 
Overall 
prevalence of 
vitamin D 
deficiency 
53.33% 10.98% 17.4% 41.46% 13.64% 80% 
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70 to 100% in general population has been reported.(73) The prevalence of vitamin D deficiency 
in our study was comparable with the previously reported studies from Tamil Nadu. Table 22 
lists a few studies from India on vitamin D deficiency. 
Table 22 - Few studies from India on vitamin D deficiency 
Author 
(reference) 
Year Place of study Study group Total number Vitamin D 
Deficiency 
(<20ng/ml) 
Zargar et 
al.(103) 
2007 Kashmir Adults 92 83% 
Vupputuri et 
al.(104) 
2006 Delhi Urban adults 105 94.3% 
Garg et 
al.(105) 
2013 Delhi Adults≥50y 1346 91.3% 
Paul et 
al.(106) 
2008 Tamil Nadu Post-menopausal 
women 
150 50% 
Paul et al.(59) 2010 Tamil Nadu HIV 
with/without 
ART & controls 
105 49.5% 
Harinarayan 
et al.(107) 
2004 Tirupathi Adults 316 69.3% 
Baidya et 
al.(108) 
2012 Kolkata Doctors 40 92.5% 
Multani et 
al.(109) 
2010 Mumbai Urban adults 214 87.5% 
Marwaha et 
al.(110) 
2011 Delhi College girls 96 100% 
(HIV – Human Immunodeficiency Virus infection; ART – Anti Retroviral Therapy) 
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In our study group, 62.22% cases and 44.44% controls were noted to have vitamin D 
deficiency (p value = 0.096). Though there was a 17.78% difference in the prevalence of vitamin 
D deficiency between the cases and control due to the overall high prevalence of vitamin D 
deficiency, our sample size was not sufficient to show any significant difference between the 
groups. In the studies by Gutte et al., Orgaz – Molina et al., Gisondi et al and Hesham Abd El-
Moaty Zaher et al., there was statistically significant difference in the prevalence of vitamin D 
deficiency between the cases and controls as shown in the table 23.(11–13,17,39,40)  
Our sample size was calculated based on the Italian study(13). In their study, only 30% of 
their controls had vitamin D deficiency whereas in our study, 44 % of our controls had vitamin D 
deficiency. This is probably a reflection of the overall high prevalence of vitamin D deficiency in 
Indian set up. 
Wilson et al., however have reported 33% of psoriasis patients versus 34.9% non-
psoriatic individuals having vitamin D deficiency (p value = 0.67).  This was an US population 
based survey of 5841 individuals aged between 20 and 59 years, where the diagnosis was based 
on self-reported psoriasis.(41) 
 The mean serum vitamin D level (ng/ml) among our cases was 21.54 ± 9.41 and that of 
our controls was 21.24 ± 10.97 (p = 0.64). The mean serum vitamin D level among our patients 
was similar to that observed in the studies by Gisondi et al.(13) and Hesham Abd El-Moaty 
Zaher et al.(39) However in their studies, their controls had a mean serum level of approximately 
37 ng/ml and in our study, it was only 21 ng /ml. Gutte et al. reported a mean serum level of 
13.53 ±3.43 ng/ml among cases and 20.80 ± 14.37 ng/ml among the controls.(17) Nawaf et al. 
from Kuwait had reported much higher mean serum values among their study subjects 
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(31.5±14.41 ng/ml among cases and 53.5±19.6 ng/ml among controls).(40) Since in their study 
they had used different reference values for vitamin D deficiency as well for metabolic syndrome 
related parameters, their data could not be used for comparison. 
Table 23 – Comparison of data on vitamin D deficiency in patients with psoriasis in 
various studies 
 
SD – Standard Deviation; Vit D – vitamin D 
 
Parameter Present study Orgaz-
Molina et 
al.(11) 
Study 1 
Orgaz -
Molina et al. 
(12) 
Study 2 
 
Gisondi et 
al(13) 
 Hesham 
Abd El-
Moaty Zaher 
et al(39) 
Gutte et 
al.(17) 
Country India Spain Spain Italy Egypt India 
VitD deficiency 
[Frequency(%) 
Case  
Control  
p- value 
 
 
28(62.22) 
20 (44.44) 
0.096 
 
 
9 (19.6) 
0(0) 
.000 
 
 
11(25.6) 
4(9.3) 
 0.043 
 
 
 
81(57.8) 
42(29.7) 
0.001 
 
 
12(25) 
0 
0.001 
 
 
48 (96) 
32 (64) 
<0.001 
Vit D (ng/ml) 
(mean±SD) 
Cases 
Controls 
p- value 
 
 
21.54±9.41 
21.24± 10.97   
0.64        
 
 
30.52 ± 9.29 
38.31 ± 9.56 
0.000 
 
 
24.41 ± 7.80 
29.53 ± 9.38 
0.007 
 
 
20.7 ± 11.3 
37.1 ± 27.6 
0.001 
 
 
21.05±3.66 
37.02±5.06 
0.000 
 
 
13.55±3.43 
20.80±14.37 
<0.001 
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Clothing pattern correlated significantly with the vitamin D level of our patients. The 
mean serum vitamin D level was only 14.48 ± 6 ng/ml among those who wore covered type of 
clothing whereas the corresponding level among those whose clothing allowed more photo- 
exposure was 23.23 ± 10.28 ng/dl (p = 0.0001).  
However the above mentioned studies did not have these parameters documented for 
comparison. Zargar et al.(103), in a study on the vitamin D status of apparently healthy adults in 
Kashmir have noted that the surface area of skin exposed affects the vitamin D status.  
The mean serum vitamin D level of our study subjects from semi-urban set up was 
16.44± 1.63 ng/dl and that of those from rural set up was 23.57± 1.48 ng/ dl.( p = 0.0004). 
Harinarayan et al. in a south Indian study showed that the prevalence of vitamin D deficiency 
was more in subjects from urban set up (85.6%) as compared to rural set up (58.6%)(107). 
However Zargar et al., in their study from Kashmir did not find any significant difference among 
the rural (80%) and urban (85.7%) subjects.(103) 
In concordance with the studies by Orgaz -Molina et al.(11) and Gisondi et al.,(13) there 
was no correlation of vitamin D level with the psoriasis disease duration or disease severity 
measures like PASI and BSA involvement. 
In our study the vitamin D level of the patients did not show significant difference with 
regard to type 1 and type 2 psoriasis. The other studies on vitamin D and psoriasis did not have 
the vitamin D correlation with early and late onset psoriasis for comparison. Park et al. in their 
study on vitamin D receptor gene polymorphisms (30) have reported a significantly higher 
frequency of ApaI polymorphism in patients with psoriasis than in healthy controls. This 
tendency was more accentuated in early onset psoriasis. 
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Orgaz -Molina et al., in their study had observed significantly lower levels of vitamin D  
in patients with metabolic syndrome (24.1 ± 7.5 ng/ml) as compared to those without metabolic 
syndrome (32.8 ± 8.9 ng/ml, p = 0.007).(11) In our study, the mean serum vitamin D levels of 
the patients with and without metabolic syndrome were 18.09 ± 7.96 ng/ ml and 24.53 ± 12.79 
ng/ ml respectively. However this difference did not reach a level of statistical significance. (p = 
0.096). 
Orgaz -Molina et al.(11,12) also observed a negative correlation between the BMI and 
vitamin D level (r = -0.30, p =0.005).The BMI of our cases showed a tendency towards negative 
correlation with the vitamin D level (r = -0.300, p = 0.045). In discordance with their study, the 
waist circumference, blood pressure and triglyceride levels did not show any correlation with the 
vitamin D level. Fasting blood sugar level of our cases showed a negative correlation with 
vitamin D level in concordance with their study (r = -0.319, p = 0.037). The HDL level of our 
cases showed a positive correlation with vitamin D level (r = 0.34, p =0.026) whereas Orgaz-
Molina et al. did not observe any correlation between vitamin D level and HDL cholesterol.(12) 
In our study, logistic regression analysis of vitamin D level could not show any 
significant changes in vitamin D level due to the presence of psoriasis after adjusting for 
clothing, skin type, locality, occupation, sun-exposure and BMI. This could be because of the 
following factors. Our sample size was small with respect to the high prevalence of vitamin D 
deficiency in the general population. The type of clothing after adjusting for the other 
confounders including sun-exposure per day showed a significant association with the vitamin D 
level in our study. In the context of psoriasis, this has important implications, as in our study we 
100 
 
observed that the cases wore more photo-protected type of clothing to avoid social 
embarrassment. The other studies on psoriasis and vitamin D level have not included this factor 
which could have partly affected the overall observed difference between the cases and controls. 
Our sample size was small and hence we could not arrive at a definitive conclusion 
regarding the difference in prevalence of vitamin D deficiency between the cases and controls, 
given the high prevalence of vitamin D deficiency in India. 
As in other studies, our study showed a high prevalence of vitamin D deficiency among 
patients with psoriasis. However though most studies found the prevalence to be significantly 
higher in psoriasis patients than in controls, our study did not show a significant difference when 
compared with ethnically comparable controls. Further studies with larger sample size are 
needed to study the effect of vitamin D on the disease and whether psoriasis is an independent 
risk factor for vitamin D deficiency. In addition to studying the role of metabolic syndrome on 
the vitamin D status of patients with psoriasis, future studies could also include parameters such 
as social avoidance and the actual sun-exposure, due to clothing styles used by the patients with 
psoriasis. 
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 Conclusions 
 
In this hospital based prospective age and sex matched case - control observational study 
from Tamil Nadu on the vitamin D status of the patients with chronic plaque psoriasis in 
comparison with the controls with minor dermatological problems between December 2013 and 
August 2014, we observed the following. 
• The overall prevalence of vitamin D deficiency (≤ 20ng/ml) in the study subjects 
was 53.33%. 
• Sixty two per cent cases and 44% controls had vitamin D deficiency with the 
observed difference not being statistically significant (p value = 0.096). 
• The mean serum vitamin D level was similar among the cases and controls, 21.54 
± 9.41ng/ml and 21.24 ± 10.97 respectively (p = 0.64). 
• There was no correlation between vitamin D level and psoriasis disease severity 
measures like PASI and BSA involvement. 
• There was no correlation between vitamin D level and duration of disease, 
presence of arthritis as well as nail changes. 
• Logistic regression analysis did not show any significant changes in vitamin D 
level attributable to the presence of psoriasis after adjusting for clothing, skin 
type, locality, occupation, sun-exposure and BMI. 
The other significant observations include: 
• Patients with psoriasis were observed to wear a more covered type of clothing 
which could have an impact on their vitamin D level. 
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• More photo-exposed type of clothing was shown to increase the serum vitamin D 
level by 47% after adjusting for skin type, locality, occupation, duration of sun- 
exposure and BMI in a logistic regression analysis when compared to wearing 
more covered type of clothing 
• Body mass index of the patients showed a tendency towards negative correlation 
with vitamin D level (r = -0.300, p = 0.045) 
• HDL level of the cases showed a positive correlation with vitamin D level (r = 
0.34, p =0.026) 
• Fasting blood sugar level of the cases showed a negative correlation with vitamin 
D level (r = -0.319, p = 0.037) 
• Significantly higher mean serum level of vitamin D (p = 0.0004) was observed in 
patients from rural set up (23.57± 1.48 ng/ dl) as compared to those from semi- 
urban set up (16.44 ± 1.63 ng/dl). 
• Residing in a rural locality was shown to increase the serum vitamin D level by 
24% after adjusting for clothing, occupation, duration of sun-exposure and BMI 
when compared to residing in a semi-urban locality. 
• Significantly higher proportion of indoor workers (p = 0.02) and those with 
average sun-exposure less than 30 minutes (p = 0.03) had vitamin D deficiency 
• Dietary intake of vitamin D among most subjects was less than one tenth of the 
recommended dietary allowance. 
• Significantly higher proportion of the cases had central obesity ( p = 0.02) and 
hypertension ( p = 0.002) as compared to controls. 
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Limitations 
 
• Our sample size was small and hence we could not arrive at a definitive conclusion 
regarding the difference in prevalence of vitamin D deficiency between the cases and 
controls, given the high prevalence of vitamin D deficiency in India. Due to constraint of 
resources (time and finances), a larger sample size was not feasible. 
• Since psoriatic patients on systemic therapy were not included in the study, patients with 
more severe disease could not be part of the study. 
• Cases and controls were not recruited around the same season of the year due to practical 
difficulties. However, in southern India where this study was conducted, sunlight is 
abundant almost throughout the year. 
• Serum Calcium, Parathyroid hormone (PTH) levels, Bone Mineral Density scan and C-
reactive protein levels could not be done due to financial constraints. 
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Recommendations  
 
• In view of the overall high prevalence of vitamin D deficiency in India, larger studies are 
needed to assess the difference in prevalence of vitamin D deficiency among patients 
with psoriasis and controls. 
• The studies on vitamin D level should include the clothing pattern of the subjects. 
• Fortification of food items with vitamin D is needed in the country given the prevalence 
of vitamin D deficiency in epidemic level. 
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Summary 
 
Background 
Psoriasis, now recognised as a systemic disease is centered on inflammation and 
involvement of cytokines of the Th1 pathway. There are recent studies showing higher 
prevalence of vitamin D deficiency in patients with psoriasis than in control groups.(10–13) 
Vitamin D acts on the vitamin D receptor (VDR) to regulate keratinocyte growth and 
differentiation. The discovery of the systemic role of vitamin D in the modulation of the immune 
system especially the Type 1 helper T cell (Th1) pathway suggests that low levels of vitamin D 
may have important implications in the pathogenesis of psoriasis.(19)  
Objectives 
Our primary objective was to determine the 25-hydroxyvitamin D status of patients with 
chronic plaque psoriasis in comparison with age and sex matched controls with non-psoriatic, 
non-photosensitive skin diseases presenting to the outpatient department (OPD) as a pilot study.  
Our secondary objective was to correlate the psoriasis disease characteristics with vitamin D 
level. 
Methods 
 Forty-five consecutive consenting patients with chronic plaque psoriasis and 45 age and 
sex matched controls with minor dermatological diseases from Tamil Nadu were recruited in this 
study. Data on demographic profile, sun-exposure, sunscreen usage, smoking, alcohol, type of 
clothing, waist circumference, vitamin D level, fasting and post prandial sugars, total cholesterol, 
triglycerides, LDL and HDL were collected from all study participants. From the patients with 
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psoriasis, data on duration of disease, disease severity as assessed by BSA and PASI, presence of 
arthritis / nail changes were also collected. 
Results 
The overall prevalence of vitamin D deficiency (≤ 20ng/ml) in the study subjects was 
53.33%. Sixty two per cent cases and 44% controls had vitamin D deficiency with the observed 
difference not being statistically significant (p value = 0.096). The mean serum vitamin D level 
was similar among the cases and controls, 21.54 ± 9.41ng/ml and 21.24 ± 10.97 respectively (p = 
0.64). There was no statistically significant difference ( p = 0.15) in the mean vitamin D level 
between patients with type 1 psoriasis (19.56 ±9.8 ng/ml) and  type 2 psoriasis (25.86 ± 12.99 
ng/ml). The mean serum vitamin D level was significantly (p = 0.0001) lower in patients who 
wore covered type of clothing (14.48 ± 6 ng/ml) when compared to the patients who wore 
clothing that allowed more photo-exposure (23.23 ± 10.28 ng/dl). With an increase in disease 
duration, there was a tendency towards decrease in vitamin D level (r = -0.2978, p = 0.047). 
There was no correlation between vitamin D level and psoriasis disease severity measures like 
PASI and BSA involvement. The vitamin D status of the patients did not differ between those 
with and without arthritis as well as between those with and without nail changes. The BMI (r = -
0.300, p = 0.045) and fasting blood sugar (r = -0.319, p = 0.037) showed a negative correlation 
and the HDL level (r = 0.34, p = 0.026) showed a positive correlation with vitamin D level 
whereas waist circumference, systolic and diastolic blood pressure, triglyceride levels as well as 
metabolic syndrome did not show any significant correlation with the vitamin D level among 
cases. 
 Logistic regression analysis did not show any significant changes in vitamin D level 
attributable to the presence of psoriasis after adjusting for clothing, skin type, locality, 
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occupation, sun-exposure and BMI. In addition, the pattern of clothing was observed to be 
strongly associated with changes in vitamin D level after adjusting for confounders. 
Limitation 
 Our sample size was small given the high prevalence of vitamin D deficiency in India 
and hence could not establish a significant difference in the prevalence of vitamin D deficiency 
between the cases and controls. 
Conclusions 
 Higher proportions of patients with psoriasis were found to have vitamin D deficiency as 
compared to the controls, but not reaching a level of statistical significance. Clothing pattern may 
have a role in the observed difference in vitamin D status. Further studies with larger sample size 
are needed to assess the association between vitamin D status and psoriasis.  
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Annexure 
 
Annexure 1 – Informed consent for cases and controls - English 
PATIENT INFORMATION SHEET 
Vitamin D and Psoriasis Vulgaris 
You are being requested to participate in a study on vitamin D and psoriasis. Psoriasis vulgaris is 
a long-term (chronic) skin problem that causes skin cells to grow too quickly, resulting in thick, 
white, silvery, or red patches of skin.  
Recently a few studies done abroad have shown that patients with psoriasis have more chances 
of vitamin D deficiency than those without the disease. We would like to find out if similar 
problem exists in patients with psoriasis in India. 
In this study, blood tests will be done to determine the vitamin D level, blood sugar level and 
cholesterol level. You will be requested to come in empty stomach for the blood tests. Five to 
10ml blood will be collected from you, once in empty stomach and once 2 hours after 
breakfast. You may experience pain and minimal bleeding at the site where blood is drawn. 
Your participation in this study is entirely voluntary and you can also decide to withdraw from 
this study. If you do so, this will not affect your usual treatment at this hospital in any way. 
For all the participants in this study, the vitamin D test will be done free of cost. 
Only those involved in the study will have access to your medical details. The results of this 
study may get published in a medical journal but your identity will not be revealed in any 
publication or presentation of results.  
If you have any further questions, please ask Dr. Priya Jeevamani C (tel: 0416 228 2054) or 
email: derm@cmcvellore.ac.in 
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INFORMATION SHEET FOR CONTROL GROUP 
Vitamin D and Psoriasis Vulgaris 
You are being requested to participate in a study on vitamin D and psoriasis. Psoriasis vulgaris is 
a long-term (chronic) skin problem that causes skin cells to grow too quickly, resulting in thick, 
white, silvery, or red patches of skin. 
Recently a few studies done abroad have shown that patients with psoriasis have more chances 
of vitamin D deficiency than those without the disease. We would like to find out if similar 
problem exists in patients with psoriasis in India. Though you do not have psoriasis, your 
participation in the study will help us to know the vitamin D status in patients without psoriasis 
for comparison. 
In this study, blood tests will be done to determine the vitamin D level, blood sugar level and 
cholesterol level. You will be requested to come in empty stomach for the blood tests. Five to 
10ml blood will be collected from you, once in empty stomach and once 2 hours after 
breakfast. You may experience pain and minimal bleeding at the site where blood is drawn. 
Your participation in this study is entirely voluntary and you can also decide to withdraw from 
this study. If you do so, this will not affect your usual treatment at this hospital in any way. 
For all the participants in this study, the vitamin D test, blood sugar level and cholesterol level 
will be done free of cost. 
Only those involved in the study will have access to your medical details. The results of this 
study may get published in a medical journal but your identity will not be revealed in any 
publication or presentation of results.  
If you have any further questions, please ask Dr. Priya Jeevamani C (tel: 0416 228 2054) or 
email: derm@cmcvellore.ac.in 
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Informed Consent form to participate in a research study  
 
Study Title: Vitamin D and Psoriasis 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published.  
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
120 
 
 
(v)  I agree to take part in the above study.  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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Annexure 2 - Informed consent for cases and controls - Tamil 
ேநாயாளகள தகவ தா 
 
ைவடமி '' ம	
 ேஸாாியா ப	றியதான ஆ 
 
 ைவடமி '' ம	
 ேஸாாியா ப	றியதான ஆவி பேக	க தகைள 
ேவகிேறா. ேஸாாியா எப  ேதா அ"#க$ விைரவாக வள&வத காரணமாக 
ஏ	ப ெசதிக+ட ,ய நீட கால ேதா ேநா. 
 
 சமீப0தி ெவளி நாகளி ெசய1பட ஒ3 சில ஆகளி ேஸாாியா 
ேநாயாளிக+#4 அ5த ேநா இலாதவ&கைள விட ைவடமி '' 4ைறபா ஏ	ப 
வா17 அதிக உ$ள  எ
 கடறிய1ப$ள . இ5தியாவி உ$ள ேஸாாியா 
ேநாயாளிகளிட அ9வித 4ைறபா உ$ளதா எ
 கடறிய உ$ேளா. 
 
 இ5த ஆவி, ைவடமி '' அள, ச&#கைர அள ம	
 ெகா:17 அள 
தீ&மானி#க இர0த பாிேசாதைன ெசய1ப. இத	காக தாக$ ெவ
 வயி	றி வ3வ  
அவசிய. ஐ5  <த ப0  மி.=. இர0த தகளிடமி35  உண#4 < ம	
 காைல 
உண#4 இர மணி ேநர0தி	41 பி எ#க1ப. இர0த எ#க1பட இட0தி 
சிறிதள வ= ம	
 இர0த# கசி வா17 உ$ள . 
 
 தாக$ இ5த ஆவி பேக	ப  தக+ைடய >ய வி31ப0தி	4 உபட . 
தாக$ இ5த ஆவி இ35  விலக < ெசயலா. இ  இ5த ம30 வமைனயி 
தாக$ ெப
 வழ#கமான சிகி@ைசைய எ5த வித0திA பாதி#கா . 
 
இ5த ஆவி பேக	4 அைனவ3#4 ைவடமி '' ேசாதைன இலவசமாக 
ெசய1ப. 
 
 இ5த ஆவி ஈப உ$ேளா& மா0திரேம தக$ ம30 வ விவரகைள அறிய 
<C. இ5த ஆவி <க$ ஒ3 ேவைள ம30 வ ப0திாி#ைககளி 
ெவளியிட1படாA தக+ைடய அைடயாள எ5த வித0திA ெவளியிட1படா . 
 
 இ5த ஆைவ1 ப	றி ேமA தகவ ெபற Dr. பிாியா ஜீவமணி அவ&கைள அ"கலா - 
ெதாைலேபசி 0416 - 2282054; email: derm@cmcvellore.ac.in. 
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தகவ தா 
 
ைவடமி '' ம	
 ேஸாாியா ப	றியதான ஆ 
 
 ைவடமி '' ம	
 ேஸாாியா ப	றியதான ஆவி பேக	க தகைள 
ேவகிேறா. ேஸாாியா எப  ேதா அ"#க$ விைரவாக வள&வத காரணமாக 
ஏ	ப ெசதிக+ட ,ய நீட கால ேதா ேநா. 
 
 சமீப0தி ெவளி நாகளி ெசய1பட ஒ3 சில ஆகளி ேஸாாியா 
ேநாயாளிக+#4 அ5த ேநா இலாதவ&கைள விட ைவடமி '' 4ைறபா ஏ	ப 
வா17 அதிக உ$ள  எ
 கடறிய1ப$ள . இ5தியாவி உ$ள ேஸாாியா 
ேநாயாளிகளிட அ9வித 4ைறபா உ$ளதா எ
 கடறிய உ$ேளா. தக+#4 
ேஸாாியா ேநா இலாதி31பிE, தகைள பாிேசாதி1பத Fல ேஸாாியா 
ேநா இலாதவ&களி ைவடமி '' நிைலைய அறிய இயA. 
 
 இ5த ஆவி, ைவடமி '' அள, ச&#கைர அள ம	
 ெகா:17 அள 
தீ&மானி#க இர0த பாிேசாதைன ெசய1ப. இத	காக தாக$ ெவ
 வயி	றி வ3வ  
அவசிய. ஐ5  <த ப0  மி.=. இர0த தகளிடமி35  உண#4 < ம	
 காைல 
உண#4 இர மணி ேநர0தி	41 பி எ#க1ப. இர0த எ#க1பட இட0தி 
சிறிதள வ= ம	
 இர0த# கசி வா17 உ$ள . 
 
 தாக$ இ5த ஆவி பேக	ப  தக+ைடய >ய வி31ப0தி	4 உபட . 
தாக$ இ5த ஆவி இ35  விலக < ெசயலா. இ  இ5த ம30 வமைனயி 
தாக$ ெப
 வழ#கமான சிகி@ைசைய எ5த வித0திA பாதி#கா . 
 
 இ5த ஆவி பேக	4 அைனவ3#4 ைவடமி '', ச&#கைர அள ம	
 
ெகா:17 அள ேசாதைன இலவசமாக ெசய1ப. 
 
 இ5த ஆவி ஈப உ$ேளா& மா0திரேம தக$ ம30 வ விவரகைள அறிய 
<C. இ5த ஆவி <க$ ஒ3 ேவைள ம30 வ ப0திாி#ைககளி 
ெவளியிட1படாA தக+ைடய அைடயாள எ5த வித0திA ெவளியிட1படா . 
 
 இ5த ஆைவ1 ப	றி ேமA தகவ ெபற Dr. பிாியா ஜீவமணி அவ&கைள அ"கலா - 
ெதாைலேபசி 0416 - 2282054; email: derm@cmcvellore.ac.in. 
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ஒ17த பவ 
 
ம30 வ ஆவி பேக	பத	கான ஒ17த பவ 
 
தைல17- ேஸாாியா ம	
 ைவடமி  ப	றிய ஆ 
 
ஆ எ: 
 
பேக	பவாி ெபய&: 
 
பிற5த ேததி/வய : 
 
1. நா..................................................... ேததியி  ேம	கட தகவ பவ0திA$ள 
அைன0  தகவகைளC ந4 ப0  அறி5  ெகாேட. இ9வாரா@சியி 
ேநா#க0ைதC இதி பெக0 #ெகா$வத Fல ஏ	ப நைமகைளC 
அறி5 ெகாேட. 
2. இ9வாரா@சியி ப4 ெகா$வ  எ வி31ப சா&5த  எபதைனC, 
இ9வாரா@சியி இ35  எ1ேபா  ேவமானாA எ#காரண< இறி விலகி# 
ெகா$ளலா எபதைனC அறி5  ெகாேட. எEைடய விலக எ ம30 வ 
சிகி@ைச#கான எ5தெவா3 உாிைமையC பாதி#கா  எபைதC அறிேவ. 
3. இ9வாரா@சி சப5தமான ெபா
1பி உ$ளவ&க$, சட1G&வமான 4:ைவ 
சா&5தவ&க$ ம	
 ஒ:4<ைற 4:ைவ சா&5தவ&க$ ம	
ம30 வஒ:4<ைற 
4:ைவ சா&5தவ&க$, எம30 வ பதிேவகைள எEைடய அEமதியிறி 
ைகயாளலா எபத	4 என  அEமதிைய ெதாிவி0 #ெகா$கிேற. இதி என#4 எ5த 
ம
17 இைல. 
4. இ9வாரா@சியி தகவக$ ம	
 <க$ அறிவிய சப5தமாக பயப0 வதி 
என#4 எ5த ம
17 இைல. 
5. நா இ9வாரா@சியி ப4 ெகா$ள <:மன ட சமதி#கிேற.   
ேநாயாளி/ சடG&வ அEமதி அளி#க1படவாி ைகெயா1ப/ைகேரைக 
 
 
 
பேக	பவாி ெபய&................................................................. ேததி....................................... 
 
பாிேசாதி1பவ& ெபய&.................................................................. 
 
சாசியாளாி ைகெயா1ப/ ெபய&.....................................................ேததி................................. 
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Annexure 3 – Clinical research form for cases 
 
CLINICAL RESEARCH FORM 
 
Vitamin D deficiency and Psoriasis Vulgaris 
 
Study ID Hospital Num.          Date           _ _ / _ _ / 201 _ 
 
 
Age Sex (1-M, 2-F) Locality (1-Urban, 2-Semi-Urban, 3-Rural) 
 
Occupation (1-Outdoor, 2-Indoor) Fitzpatrick Skin Type (3, 4, 5, 6) 
 
 
Avg. Sun hours: week day (hh:mm) week end (hh:mm) 
 
Sun screen usage (1-Always, 2-Mostly, 3-Occasional, 4-Never) SPF (if used) 
 
Clothing (1 Face, 2 Hand/Feet/Neck, 3 Forearms, 4 Waist, 5 Legs)  
 
Family history of Psoriasis (1-Yes, 0-No, 2-Doubtful)  
 
 
Smoking (1-Yes, 0-No)   If yes, avg. Cigars/day No. of years  
  
Alcohol (1-Yes, 0-No) If yes, frequency (1-Daily, 2-Weekly, 3-Monthly, 4-Occational 
 
Avg. quantity alcohol/week (in ml.) No. of years of alcohol 
 
Avg./week: Fish (gms) Milk (ml) Milk fortified (1-Yes,0-No)  
 
 
Diabetic (1-Y,0-N) If yes, num yrs Treatment (1-Drugs, 2-Diet) 
 
Hypertensive (1-Yes, 0-No) If yes, duration (in years)  
 
Dyslipidemia (1-Yes, 0-No) If yes, treatment (1-Drugs, 2-Diet control)  
 
 
Weight (kg) Height (cms) BMI  
 
BP1 BP2 AC PC  
 
Waist (cms) Total Cholesterol Triglycerides  
 
HDL LDL Vitamin D level 
  
 
Is Control? (1-Yes, 0-No) 
 
Onset age Exacerbation (0-No Season, 1-Winter, 2-Summer) 
 
Avoidance due to ds? (1-Y, 0-N)         Reason (1-Social, 2-Disability, 3-Others)  
 
Topical treatment   ------------------------------------------------------------------------------------ 
 
---------------------------------------------------------------------------------------------------------------------------- 
 
Systemic treatment ------------------------------------------------------------------------------------ 
 
---------------------------------------------------------------------------------------------------------------------------- 
   
       
  
 
 
 
 
  :     :   
   
 
 
 
  
  .   
 
 
      
    
 
    
   .    
 
  .   
 
 
   .        .   
   /    
   /    
   
   
   .  
      
  
     .   
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Phototherapy in last one year (1-Yes, 0-No) 
 
Nail Involvement (1-Yes, 0-No) NAPSI score  
 
Arthritis (1-Yes, 0-No) Caspar Score Moll & Wright type  
 
Is Arthritis Symptomatic now? (1-Yes, 0-No) 
 
Total BSA involvement in percentage 
 
PASI  
 
 
 
 
 
   
 
 
 
 
  .   
  .   
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Arthritis 
 
Moll and Wright subgroups  
 
1 DIP joint only 
2 Asymmetrical oligoarthritis 
3 Polyarthritis 
4 Spondylitis 
5 Arthritis mutilans 
 
CASPAR score 
 
1 Skin psoriasis present - 2 
 Past - 1 
 Fa/h If pt not affected - 1 
2 Nail (pits/ onycholysis/ hyperkeratosis)             1 
3 Dactylitis                                                             1 
4 Rheumatoid factor negative                                1 
5 Juxtaarticular new bone formation                     1 
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Annexure 4 - Clinical research form for controls 
 
CLINICAL RESEARCH FORM 
 
Vitamin D deficiency and Psoriasis Vulgaris 
 
Study ID Hospital Num.          Date           _ _ / _ _ / 201 _ 
 
 
Age Sex (1-M, 2-F) Locality (1-Urban, 2-Semi-Urban, 3-Rural) 
 
Occupation (1-Outdoor, 2-Indoor) Fitzpatrick Skin Type (3, 4, 5, 6) 
 
 
Avg. Sun hours: week day (hh:mm) week end (hh:mm) 
 
Sun screen usage (1-Always, 2-Mostly, 3-Occasional, 4-Never) SPF (if used) 
 
Clothing (1 Face, 2 Hand/Feet/Neck, 3 Forearms, 4 Waist, 5 Legs)  
 
Family history of Psoriasis (1-Yes, 0-No, 2-Doubtful)  
 
 
Smoking (1-Yes, 0-No)   If yes, avg. Cigars/day No. of years  
  
Alcohol (1-Yes, 0-No) If yes, frequency (1-Daily, 2-Weekly, 3-Monthly, 4-Occational 
 
Avg. quantity alcohol/week (in ml.) No. of years of alcohol  
 
 
Avg./week: Fish (gms) Milk (ml) Milk fortified (1-Yes,0-No)  
 
 
Diabetic (1-Y,0-N) If yes, num yrs Treatment (1-Drugs, 2-Diet) 
 
Hypertensive (1-Yes, 0-No) If yes, duration (in years)  
 
Dyslipidemia (1-Yes, 0-No) If yes, treatment (1-Drugs, 2-Diet control)  
 
 
Weight (kg) Height (cms) BMI  
 
BP1 BP2 AC PC  
 
Waist (cms) Total Cholesterol Triglycerides  
 
HDL LDL Vitamin D level  
 
 
Is Control? (1-Yes, 0-No) 
 
Dermatological diagnosis:    ------------------------------------------------------------------------ 
 
BSA Percentage:  
 
   
       
  
 
 
 
 
  :     :   
   
 
 
 
  
  .   
 
 
      
    
 
    
   .    
 
  .   
 
 
   .        .   
   /    
   /    
   
   
   .  
      
  
     .   
 
  
  .   
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Annexure 5 – Criteria for metabolic syndrome and central obesity 
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Annexure 6 – Master chart 
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P01 28/01/2014 33 2 3 1 5 7 1 4   4 0 0     0       0 200 0 0     
P02 15/02/2014 27 2 2 2 4 0.3 0.3 4   3 0 0     0       500 100 0 0     
P03 22/02/2014 20 2 2 1 4 2 1 4   4 0 0     0       200 200 0 0     
P04 22/02/2014 20 2 3 2 5 0.15 0.3 4   3 0 0     0       50 200 0 0     
P05 22/02/2014 34 1 3 2 5 2 0.3 4   2 0 1 5 5 1 4 50 2 100 250 0 0     
P06 27/02/2014 42 1 3 1 5 8 2 4   3 0 0     0       0 100 0 0     
P07 27/02/2014 24 1 2 2 4 2 0.3 4   2 0 0     0       0 250 0 0     
P08 01/03/2014 27 1 2 2 5 1 0.3 4   3 0 0     0       200 300 0 0     
P09 04/03/2014 21 1 2 2 5 8 3 4   3 0 0     0       50 200 0 0     
P10 06/03/2014 44 2 3 2 4 0.3 1 4   4 0 0     0       0 300 0 0     
P11 08/03/2014 51 2 3 2 5 0.15 0.3 4   4 0 0     0       50 500 0 0     
P12 22/02/2014 54 2 2 2 5 0.15 1 4   4 0 0     0       600 400 0 0     
P13 18/03/2014 44 1 3 1 5 5 3 4   3 0 0     0       0 300 0 0     
P14 18/03/2014 44 1 2 1 5 5 2 4   3 0 0     1 2 200 2 100 200 0 0     
P15 22/03/2014 59 1 2 2 5 0.3 0.3 4   2 0 0     0       0 300 0 1 1 1 
P16 01/04/2014 35 1 3 2 5 1 1 4   3 0 0     0       50 100 0 0     
P17 01/04/2014 37 1 3 1 5 3 2 4   2 1 0     0       50 250 0 0     
P18 01/04/2014 44 1 3 2 4 0.3 0.3 4   2 0 0     0       100 300 0 1 4 1 
P19 08/04/2014 59 1 2 1 5 8 6 4   3 0 0     1 4 50 10 0 300 0 1 1 1 
P20 26/04/2014 50 1 3 2 5 1 2 4   2 0 0     0       0 300 0 0     
P21 24/04/2014 60 1 3 2 5 2 2 4   2 0 0     0       100 200 0 1 8 1 
P22 01/05/2014 27 2 2 2 5 0.15 0.3 4   4 0 0     0       100 500 0 0     
P23 05/06/2014 36 1 2 1 5 5 5 4   3 0 0     0       0 400 0 0     
P24 06/06/2014 39 1 3 1 5 3 2 4   3 0 0     1 4 10 5 0 200 0 0     
P25 06/06/2014 28 1 2 2 5 2 3 4   2 0 0     1 4 5 3 200 400 0 0     
P26 10/06/2014 51 2 3 1 5 4 4 4   4 0 0     0       0 300 0 0     
P27 12/06/2014 54 1 2 1 5 0.3 0.3 4   3 0 0     0       0 200 0 1 4 2 
P28 14/06/2014 36 2 3 1 5 3 1 4   4 0 0     0       0 100 0 0     
P29 14/06/2014 33 1 2 1 5 1 2 4   2 0 1 1 2 0       0 300 0 0     
P30 17/06/2014 62 2 2 2 4 0.3 0.3 4   1 0 0     0       0 100 0 1 10 1 
P31 17/06/2014 25 2 2 2 5 1 1 4   3 0 0     0       0 300 0 0     
P32 17/06/2014 65 1 3 1 5 8 8 4   3 0 0     1 4 50 5 0 200 0 0     
P33 28/06/2014 44 1 3 1 5 8 2 4   5 1 0     1 4 50 15 0 200 0 0     
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P34 28/06/2014 56 2 2 2 4 0.15 0.15 4   4 0 0     0       200 150 0 0     
P35 28/06/2014 30 2 2 2 4 0.1 0.1 4   1 0 0     0       100 250 0 0     
P36 01/07/2014 38 1 1 2 5 0.3 0.3 4   2 1 0     0       0 0 0 0     
P37 03/07/2014 59 1 2 2 5 0.2 0.3 4   2 1 1 4 10 1 3 25 8 200 350 0 1 14 1 
P38 03/07/2014 50 2 2 2 4 0.3 0.3 4   4 0 0     0       150 250 0 1 0.25 2 
P39 03/07/2014 59 2 3 2 5 0.15 0.3 4   4 1 0     0       50 300 0 0     
P40 03/07/2014 40 1 2 1 5 5 4 4   2 0 1 3 15 0       0 250 0 0     
P41 03/07/2014 34 2 3 2 5 0.3 2 4   4 0 0     0       200 400 0 0     
P42 05/07/2014 35 2 3 1 5 6 2 4   4 0 0     0       0 200 0 0     
P43 08/07/2014 41 2 3 1 5 5 4 4   4 0 0     0       50 250 0 0     
P44 10/07/2014 57 1 2 1 5 2 1 4   3 1 0     0       150 300 0 0     
P45 10/07/2014 48 1 2 2 5 0.3 0.3 4   2 0 1 2 20 0       0 300 0 1 10 1 
P46 12/07/2014 41 1 2 1 5 5 4 4   2 0 0     0       0 300 0 0     
P47 12/07/2014 48 1 3 2 5 1 0.3 4   3 0 0     0       0 350 0 0     
P48 13/03/2014 56 1 2 2 5 0.3 0.3 4   3 0 0     0       0 200 0 0     
P49 17/07/2014 51 2 2 2 5 0.3 0.3 4   4 0 0     0       100 0 0 1 10 1 
P50 22/07/2014 26 1 3 1 5 6 5 4   3 0 0     1 4 10 3 0 0 0 0     
P51 02/08/2014 35 1 2 2 4 1 1 4   2 0 1 12 10 0       50 150 0 0     
P52 05/08/2014 44 2 3 1 5 0.3 0.3 4   4 0 0     0       100 300 0 1 6 1 
P53 14/08/2014 59 1 2 2 4 0.3 0.3 4   3 0 0     1 1 630 2 50 0 0 1 5 1 
C01 03/06/2014 20 2 2 2 4 0.3 1 3 15 3 0 0     0       0 300 0 0     
C02 05/06/2014 44 1 2 2 4 0.3 1 4   2 0 0     0       50 400 0 0     
C03 10/06/2014 53 2 3 2 5 0.3 1 4   4 0 0     0       100 100 0 1 2 1 
C04 10/06/2014 53 1 3 1 5 8 8 4   5 0 0     0       100 200 0 0     
C05 17/06/2014 42 2 3 1 5 8 5 4   4 0 0     0       0 50 0 0     
C06 17/06/2014 31 2 2 2 4 1 0.3 4   4 0 0     0       50 150 0 0     
C07 17/06/2014 46 1 2 2 5 0.1 1 4   3 0 0     0       200 150 0 0     
C08 17/06/2014 33 1 3 1 5 8 6 4   5 0 0     0       50 50 0 0     
C09 19/06/2014 34 1 2 1 5 8 6 4   3 0 0     0       0 300 0 0     
C10 21/06/2014 18 2 2 2 5 0.3 0.3 4   3 0 0     0       100 250 0 0     
C11 24/06/2014 50 2 2 2 4 0.3 0.3 4   4 0 0     0       0 300 0 1 5 1 
C12 24/06/2014 27 2 3 1 5 2 1 4   4 0 0     0       0 50 0 0     
C13 24/06/2014 24 1 2 1 5 6 1 4   2 0 0     0       0 150 0 0     
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C14 26/06/2014 24 1 2 1 5 1 1 4   3 0 0     0       200 250 0 0     
C15 01/07/2014 34 2 2 1 4 0.2 0.2 4   4 0 0     0       0 200 0 0     
C16 01/07/2014 52 1 2 1 5 2 1 4   3 0 1 3 20 0       50 300 0 0     
C17 01/07/2014 35 1 2 2 5 0.15 0.3 3 15 2 0 0     0       100 250 0 0     
C18 03/07/2014 30 1 2 1 5 6 6 4   3 0 0     0       0 250 0 0     
C19 03/07/2014 37 1 2 2 5 2 1 4   3 0 0     0       50 400 0 1 3 1 
C20 03/07/2014 32 1 2 2 4 0.15 0.3 4   3 0 0     0       0 100 0 0     
C21 12/07/2014 52 2 3 2 5 0.3 0.3 4   4 0 0     0       100 200 0 0     
C22 17/07/2014 52 2 3 1 5 6 6 4   4 0 0     0       150 300 0 0     
C23 17/07/2014 24 2 2 2 4 0.3 0.3 4   4 0 0     0       0 250 0 0     
C24 22/07/2014 35 2 2 2 5 0.2 0.2 2 30 3 0 0     0       50 350 0 0     
C25 24/07/2014 27 1 2 2 5 3 3 4   3 0 0     0       0 300 0 0     
C26 02/08/2014 37 1 3 1 5 6 6 4   5 0 0     0       0 200 0 0     
C27 05/08/2014 60 1 3 1 5 6 6 4   5 0 0     0       0 150 0 0     
C28 05/08/2014 37 2 2 2 4 0.3 1 4   4 0 0     0       100 200 0 0     
C29 07/08/2014 34 2 3 2 5 1 2 4   4 0 0     0       100 200 0 0     
C30 12/08/2014 39 2 2 2 4 0.3 0.3 4   3 0 0     0       0 100 0 0     
C31 12/08/2014 44 1 2 2 5 1 1 4   3 0 1 5 25 0       0 300 0 0     
C32 03/07/2014 21 1 2 2 5 0.3 0.3 4   3 0 0     0       0 250 0 0     
C33 14/08/2014 25 2 3 2 5 0.45 0.3 4   4 0 0     0       0 250 0 0     
C34 14/08/2014 41 1 3 1 4 8 8 4   5 0 1 5 15 1 2 90 8 0 300 0 0     
C35 14/08/2014 39 1 3 1 5 3 3 4   3 0 0     0       0 300 0 0     
C36 13/08/2014 42 2 3 2 5 0.3 0.3 4   4 0 0     0       50 600 0 0     
C37 16/08/2014 38 1 2 1 5 2 2 4   3 0 1 10 15 0       100 300 0 0     
C38 16/08/2014 58 2 2 2 4 0.3 0.3 4   4 0 0     0       100 300 0 0     
C39 21/08/2014 42 1 2 2 5 0.3 1 4   3 0 0     0       50 200 0 1 2 1 
C40 21/08/2014 59 1 2 2 5 1 1 4   3 0 1 20 25 0       100 350 0 0     
C41 21/08/2014 52 1 2 2 5 2 3 3 26 3 0 0     0       50 200 0 1 5 1 
C42 26/08/2014 57 1 3 1 5 8 8 4   3 0 0     0       100 200 0 0     
C43 26/08/2014 46 1 2 1 5 0.3 0.3 4   2 0 1 10 30 1 4 30 30 0 450 0 1 12 1 
C44 26/08/2014 64 2 2 2 5 0.3 0.3 4   4 0 0     0       0 300 0 0     
C45 26/08/2014 46 1 2 1 5 6 5 4   2 0 0     0       0 100 0 1 1 1 
C46 29/08/2014 59 1 3 1 5 5 4 4   3 0 0     0       0 250 0 0     
C47 30/08/2014 65 1 2 2 5 1 1 4   3 0 0     0       0 300 0 0     
 
 
133 
 
St
u
dy
 
id
 
H
yp
er
te
n
sio
n
 
H
T 
du
ra
tio
n
 
D
ys
lip
id
em
ia
 
D
ys
.
 
Tr
ea
tm
en
t 
W
ei
gh
t 
H
ei
gh
t 
B
M
I 
SB
P1
 
D
B
P1
 
SB
P1
 
D
B
P1
 
W
ai
st
 
A
C 
PC
 
Ch
o
le
st
er
o
l 
Tr
ig
ly
ce
rid
es
 
H
D
L 
LD
L 
V
ita
m
in
 
D
 
P01 0   0   65 158 26 100 70 110 70 78 82 126         30.7 
P02 0   0   64 156 26.3 116 70 110 70 88 90 103 138 67 48 82 11.57 
P03 0   0   57.5 151 25.2 116 70 110 70 81 102 111 137 89 27 93 28.93 
P04 0   0   40 154 16.9 100 70 96 70 64 74 84 102 68 35 58 10.65 
P05 0   0   61 174 20.1 140 70 146 78 85               
P06 0   0   50 161 19.3 110 80 110 76 77 93 97 124 80 43 69 16.37 
P07 0   0   61 165 22.4 110 70 106 70 78 93 91 221 126 46 152 18.2 
P08 0   0   64 163 24.1 120 80 120 76 81 111 136 204 251 49 136   
P09 0   0   54 163 20.3 116 80 110 76 72 81 81 159 152 34 110 17.73 
P10 0   0   103 160 40.2 160 90 150 90 112 85 90 156 94 40 99 17.6 
P11 0   0   74 159 29.3 100 70 100 70 94               
P12 0   0   64 160 25 140 84 140 90 90 115 119 197 80 48 122 28.6 
P13 0   0   64 170 22.1 110 84 110 86 82               
P14 0   0   70 165 25.7 124 80 120 80 94 92 102 125 63 33 84 39.37 
P15 1 3 0   84 163 31.6 150 96 150 90 110 162 216 113 69 38 64 5.92 
P16 0   0   84 167 30.1 140 90 140 90 102 151 138 218 270 36 149 15.78 
P17 0   0   83 178 26.2 140 100 140 100 99 88 89 194 118 42 138 21.58 
P18 1 4 1 1 67 167 24 150 96 150 90 90 139 129 129 228 51 71 14.02 
P19 1 2 1 1 83 172 28.1 150 96 156 90 107 107 249 167 134 40 105   
P20 0   0   80 164 29.7 140 94 140 96 100 90 111 188 210 32 124 19.44 
P21 0   1 1 70 162 26.7 130 80 130 80 96 110 126 157 185 39 99 19.62 
P22 0   0   63.5 165 23.3 130 86 130 80 75 85 112 120 64 30 86 20.66 
P23 0   0   67 167 24 130 80 130 80 87 85 96 160 63 53 101 18.33 
P24 0   0   76 164 28.3 120 80 120 76 98 91 113 198 76 40 137 32.57 
P25 0   0   74 187 21.2 150 100 130 90 80 87 109 217 137 48 149 29.07 
P26 0   0   68 161 26.2 156 100 150 100 84 95 107 182 111 47 116 40.48 
P27 0   0   89 167 31.9 140 100 140 100 115 121 258 232 107 54 162 17.38 
P28 0   0   73 159 28.9 120 70 114 70 90 84 105 110 116 25 72 20.36 
P29 0   0   63 165 23.1 120 80 120 80 90               
P30 1 8 1 2 85 162 32.4 150 100 150 96 96 205 239 162 225 31 104 7.02 
P31 0   0   103 156 42.3 156 100 150 100 102 102 104 142 73 36 96 8.41 
P32 0   0   45 157 18.3 130 80 130 80 73 101 113 147 72 32 112 36.24 
P33 0   0   75 168 26.6 110 80 110 80 99 87 111 217 134 55 148 49.67 
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P34 0   0   77.5 158 31 130 80 124 78 95 101 105           
P35 0   0   58 162 22.1 110 70 106 70 81 91 87 142 125 35 95 15.8 
P36 0   0   95 170 32.9 140 100 142 96 111 89 70 170 115 36 122 9.22 
P37 0   0   70 159 27.7 124 80 120 80 98               
P38 1 10 1 1 71 153 30.3 170 100 160 100 94 119 181 109 106 42 56 16.12 
P39 0   1 2 69 144 33.3 150 90 150 86 94 99 110 208 125 47 144 12.14 
P40 0   0   84 178 26.5 140 80 140 76 105   116         5.19 
P41 1 0.25 0   94 150 41.8 160 106 156 104 101 103 99 186 78 38 129 15.98 
P42 0   0   67 154 28.3 120 80 120 76 92 239 230 133 546 24 44 18.7 
P43 0   0   55 153 23.5 110 80 110 74 74 89 103 151 120 51 95 26.91 
P44 0   0   102 175 33.3 140 90 146 90 118 105 156 208 88 44 152 17.87 
P45 0   0   83 165 30.5 140 100 146 100 114 116 203 199 263 36 139 15.79 
P46 0   0   63 157 25.6 130 90 130 84 90 105 121 194 288 36 136 19.32 
P47 0   0   65 170 22.5 170 110 160 110 94   255         37.05 
P48 1 1.5 1 1 68 162 25.9 130 80 120 76 84 97 140 158 187 41 86 28.81 
P49 0   1 1 69 150 30.7 130 80 134 80 92 107 122 137 144 54 80 22.99 
P50 0   0   57 157 23.1 120 74 120 70 79 76 86 234 193 63 161 53.89 
P51 0   0   59 175 19.3 120 70 120 66 75 78 81 189 117 34 139 10.19 
P52 0   0   56 158 22.4 150 80 146 80 77 143 229 180 99 55 110 17.48 
P53 1 3 1 1 80 165 29.4 130 100 130 96 105 175 210 167 153 31 113 15.91 
C01 0   0   74 170 25.6 106 70 100 70 79 77 74 116 40 52 63 8.21 
C02 0   0   72 173 24.1 110 80 110 80 88 90 101 235 189 35 175 11.17 
C03 0   0   90 160 35.2 120 80 120 80 105 106 152 128 129 36 83 34.51 
C04 0   0   45 160 17.6 120 80 120 80 70 83 148 190 86 64 112 51.62 
C05 0   0   52 165 19.1 120 70 114 70 66 77 89 99 38 46 60 22.16 
C06 0   0   59 157 23.9 120 70 124 66 82 82 107 133 54 31 94 29.52 
C07 0   1 2 65 165 23.9 140 90 130 82 84 135 128 187 182 37 134 15.16 
C08 0   0   55 161 21.2 120 84 120 84 82 159 202 177 107 46 124 16.92 
C09 0   0   84 164 31.2 160 100 152 100 92 86 102 143 101 29 98 21.24 
C10 0   0   40 153 17.1 100 70 104 70 57 81 80 135 64 42 85 12.72 
C11 0   0   60 153 25.6 150 96 150 90 88 143 171 201 241 30 161 13.95 
C12 0   0   40 147 18.5 120 76 120 70 60 85 86 122 35 46 75 22.76 
C13 0   0   75 186 21.7 110 76 110 70 86 89 95 162 90 47 106 11.47 
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C14 0   0   85 174 28.1 140 80 132 84 98               
C15 0   0   81 162 30.9 120 80 116 80 92 93 98 181 196 32 128 14.89 
C16 0   0   65 163 24.5 120 70 120 76 94 104 180 181 78 28 139 16.42 
C17 0   1 2 79 178 24.9 120 80 120 80 95 93 114 163 116 21 82 13.46 
C18 0   0   60 171 20.5 110 80 110 80 86 88 135 138 73 51 87 22.4 
C19 0   0   85 161 32.8 100 76 100 80 108             31.65 
C20 0   0   105 174 34.7 120 90 120 86 111 100 113 178 63 51 117 13.85 
C21 0   0   69 160 27 110 70 110 74 88 96 106 199 135 40 139 31.04 
C22 0   0   64 152 27.7 110 70 104 70 91 111 86 223 163 34 169 30.52 
C23 0   0   57.5 156 23.6 120 76 126 70 80             17.81 
C24 0   0   45 152 19.5 90 70 90 70 64 93 91 165 44 61 102 13.63 
C25 0   0   62 165 22.8 120 70 116 70 86 105 89 195 102 39 135 16.04 
C26 0   0   59 164 21.9 110 70 100 70 81 87 105 152 80 35 103 23.47 
C27 0   0   55 165 20.2 120 80 120 76 71 85 189 181 95 41 125 24.8 
C28 0   0   88 165 32.3 130 80 130 80 94 102 93 157 65 37 100 31.15 
C29 0   0   60 161 23.1 120 76 120 70 82 87 105 190 59 55 122 28.83 
C30 0   0   55 153 23.5 120 80 120 80 79 94 71 186 153 44 119 43.34 
C31 0   0   62.5 162 23.8 130 90 130 86 84 101 186 157 108 37 101 10.7 
C32 0   0   75 169 26.3 120 80 120 80 74   82 191 86 57 127 15.57 
C33 0   0   50 155 20.8 110 70 100 70 70             20.1 
C34 0   0   80 169 28 110 80 110 80 97 109 98 216 205 46 157 16.99 
C35 0   0   67.5 165 24.8 120 80 120 80 88   86         23.85 
C36 0   0   102 167 36.6 130 80 126 80 98 95 97 159 101 34 109 20.06 
C37 0   0   102 168 36.1 150 110 150 106 116 81 98 197 169 28 139 24.57 
C38 0   0   74 156 30.4 120 70 120 76 90 91   206 120 33 147 21.23 
C39 0   0   64 168 22.7 130 84 130 80 80 106 88 141 328 25 83 6.02 
C40 0   0   57 165 20.9 120 80 120 80 80 93 167 155 69 24 111 28.28 
C41 0   0   75 170 26 130 78 130 80 86 92 177 136 111 47 79 9.28 
C42 0   0   64 178 20.2 120 90 120 86 84 86 85 141 56 43 90 26.89 
C43 0   1 1 72 168 25.5 120 80 116 80 90 79 180 99 114 35 55 16.56 
C44 1 1 0   55 149 24.8 110 70 110 74 90 85 122 198 111 52 134 26 
C45 0   0   60 170 20.8 130 86 130 80 84 116 136 134 235 33 75 12.17 
C46 0   0   56 162 21.3 130 70 130 80 81 95 138 116 88 35 73 23.23 
C47 0   0   54 158 21.6 120 80 114 76 80 99 115 175 100 46 121 36.76 
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P01 0     24 0 0   1 1 2 1 4 3 1 30 15.6 
P02 0     12 0 0   1 1 2 0       5 5 
P03 0     17 1 0   1 1 1 0       20 8.9 
P04 0     19 0 0   3 1 3 0       8 2.4 
P05 0     32 1 1 1 5 1 6 0       15 7.5 
P06 0     30 0 0 0 8 1 6 0       10 6.3 
P07 0     21 1 1 1 8 1 22 0       5 6.4 
P08 0     26 0 0 0 2 1 3 0       5 4.1 
P09 0     5 1 0 0 1 1 2 0       20 10.3 
P10 0     41 0 0   2 1 4 0       5 3.2 
P11 0     48 0 0   2 1 4 0       5 5.2 
P12 0     18 1 0   2 1 3 0       10 4.7 
P13 0     42 1 0   3 1 29 0       8 4.1 
P14 0     40 0 0   1 1 6 0       8 7.2 
P15 0     56 2 0   8 0   0       4 1.4 
P16 0     30 1 1 1 7 1 7 0       5 6.1 
P17 0     28 1 1 1 7 1 10 0       50 15.6 
P18 0     37 0 0   5 1 1 0       5 5.6 
P19 0     55 2 0   7 1 4 0       8 5.3 
P20 0     23 1 1 1 8 1 7 0       5 3.2 
P21 0     45 1 0   1 0   0       3 2 
P22 0     25 1 0   1 0   0       3 3.3 
P23 0     34 2 0   7 1 20 0       4 3 
P24 0     25 2 1 1 8 1 14 1 4 3 1 5 4.5 
P25 0     25 2 0   2 0   0       3 1.6 
P26 0     49 1 0   2 1 5 0       5 2.2 
P27 0     30 2 1 1 6 1 5 0       10 8 
P28 0     33 0 0   6 0   0       5 3 
P29 0     28 0 0   1 1 22 1 4 2 1 5 2.6 
P30 0     10 0 0   1 1 1 0       3 1.6 
P31 0     12 1 1 1 2 0   0       8 5 
P32 0     60 0 1 1 7 1 15 0       35 16.2 
P33 0     40 0 0   2 1 1 0       6 4.8 
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P34 0     52 1 0   1 0   0       5 5.2 
P35 0     26 0 0   2 1 6 0       4 4 
P36 0     15 1 0   2 1 4 0       3 2 
P37 0     35 0 0   1 0   0       4 5.2 
P38 0     35 0 0   3 0   0       4 2.4 
P39 0     25 1 0   2 1 6 0       5 4.6 
P40 0     17 2 1 1 1 1 11 1 2 4 1 15 7.2 
P41 0     34 0 0   1 0   0       8 6.6 
P42 0     31 0 0   1 1 37 0       7 7.4 
P43 0     35 1 0   1 0   0       4 4 
P44 0     50 0 0   8 0   0       3 3 
P45 0     40 0 0   2 1 3 0       3 2 
P46 0     35 1 1 1 6 0   0       3 0.9 
P47 0     38 0 0   7 1 15 0       8 6.7 
P48 0     52 1 0   2 1 6 1 5 2 1 2 1.5 
P49 0     46 1 1 1 1 0   0       5 4.6 
P50 0     24 0 1 1 2 0   0       12 7.4 
P51 0     34 0 1 1 2 1 3 0       8 6.4 
P52 0     22 1 1 1 2 0   1 4 3 1 5 5.6 
P53 0     58 0 0   1 0   0       4 3.6 
C01 1 1 1                           
C02 1 1 1                           
C03 1 2 1                           
C04 1 1 5                           
C05 1 3 0                           
C06 1 2 1                           
C07 1 4 1                           
C08 1 2 1                           
C09 1 1 2                           
C10 1 1 1                           
C11 1 2 1                           
C12 1 5 1                           
C13 1 6 2                           
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C14 1 7 1                           
C15 1 2 1                           
C16 1 8 1                           
C17 1 9 1                           
C18 1 1 5                           
C19 1 10 1                           
C20 1 11 1                           
C21 1 1 1                           
C22 1 8 3                           
C23 1 8 2                           
C24 1 12 1                           
C25 1 13 2                           
C26 1 8 2                           
C27 1 14 2                           
C28 1 15 1                           
C29 1 14 2                           
C30 1 7 1                           
C31 1 1 3                           
C32 1 10 1                           
C33 1 16 1                           
C34 1 17 5                           
C35 1 11 1                           
C36 1 12 2                           
C37 1 17 5                           
C38 1 9 1                           
C39 1 6 3                           
C40 1 7 1                           
C41 1 15 1                           
C42 1 7 1                           
C43 1 1 4                           
C44 1 15 1                           
C45 1 18 1                           
C46 1 7 1                           
C47 1 7 1                           
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Age and sex matched pairs of cases and controls: 
Pair 
ID 
Study 
ID Age Sex Case/Ctrl 
Pair 
ID 
Study 
ID Age Sex Case/Ctrl 
Pair 
ID 
Study 
ID Age Sex Case/Ctrl 
1 P01 33 Female case 16 P21 60 Male case 31 P39 59 Female case 
1 C15 34 Female control 16 C40 59 Male control 31 C38 58 Female control 
2 P02 27 Female case 17 P22 27 Female case 32 P40 40 Male case 
2 C33 25 Female control 17 C12 27 Female control 32 C35 39 Male control 
3 P03 20 Female case 18 P23 36 Male case 33 P41 34 Female case 
3 C01 20 Female control 18 C09 34 Male control 33 C24 35 Female control 
4 P04 20 Female case 19 P24 39 Male case 34 P42 35 Female case 
4 C10 18 Female control 19 C19 37 Male control 34 C28 37 Female control 
5 P06 42 Male case 20 P25 28 Male case 35 P43 41 Female case 
5 C34 41 Male control 20 C18 30 Male control 35 C30 39 Female control 
6 P07 24 Male case 21 P26 51 Female case 36 P44 57 Male case 
6 C13 24 Male control 21 C11 50 Female control 36 C42 57 Male control 
7 P09 21 Male case 22 P27 54 Male case 37 P45 48 Male case 
7 C32 21 Male control 22 C41 52 Male control 37 C43 46 Male control 
8 P10 44 Female case 23 P28 36 Female case 38 P46 41 Male case 
8 C05 42 Female control 23 C29 34 Female control 38 C39 42 Male control 
9 P12 54 Female case 24 P30 62 Female case 39 P47 48 Male case 
9 C03 53 Female control 24 C44 64 Female control 39 C45 46 Male control 
10 P14 44 Male case 25 P31 25 Female case 40 P48 56 Male case 
10 C02 44 Male control 25 C23 24 Female control 40 C04 54 Male control 
11 P15 59 Male case 26 P32 65 Male case 41 P49 51 Female case 
11 C27 60 Male control 26 C47 65 Male control 41 C21 52 Female control 
12 P16 35 Male case 27 P33 44 Male case 42 P50 26 Male case 
12 C08 33 Male control 27 C31 44 Male control 42 C25 27 Male control 
13 P17 37 Male case 28 P35 30 Female case 43 P51 35 Male case 
13 C26 37 Male control 28 C06 31 Female control 43 C17 35 Male control 
14 P18 44 Male case 29 P36 38 Male case 44 P52 44 Female case 
14 C07 46 Male control 29 C37 38 Male control 44 C36 42 Female control 
15 P20 50 Male case 30 P38 50 Female case 45 P53 59 Male case 
15 C16 52 Male control 30 C22 52 Female control 45 C46 59 Male control 
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Keys to Master chart 
1. Study id Study identification number 
- P01 to P53  - Cases 
- C01 to C47 - Controls 
2. Date  Date of recruitment 
- <dd/mm/yyyy> 
3. Age  Age in years 
4. Sex   Gender 
- 1 male, 2 female 
5. Locality Locality of the study subjects 
- 1 urban, 2 semi-urban, 3 rural 
6. Occupation Occupation of the subjects 
- 1 Outdoor, 2 Indoor 
7. Skin type  Fitzpatrick Skin Type 
8. wkdaysunhrs  Average hours of sun-exposure on week days (hh:mm) 
9. wkendsunhrs  Average hours of sun-exposure on weekends (hh:mm) 
10. sunscreen Sunscreen usage pattern 
- 1 Always (Even Indoors), 2 Mostly 
(Avg. five days in a week), 3 Occasional 
(Not more than two days in a week), 4 
Never 
11. SPF  Sun protection factor 
12. Clothing Type of clothing while outdoor 
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- 1 Only face exposed (e.g. burqa), 2 Face, 
hands, feet & neck exposed (e.g. full 
sleeved shirt), 3 Forearms exposed (e.g. 
half sleeved shirt), 4 Waist exposed (e.g. 
sari), 5 Legs (e.g. dhoti only) 
13. Family history  Family history of Psoriasis 
- 1 yes, 0 no, 2 doubtful 
14. Smoking  Smoking 
- 1 yes, 0 no 
15. Cigar./day  Average number of cigarettes smoked per day 
16. Cigar years  Number of years of smoking 
17. Alcohol  Alcohol consumption 
- 1 yes, 0 no 
18. Alc. Freq.  Frequency of alcohol intake 
- 1 Almost daily, 2 Weekly, 3 Monthly, 4 
Occasional 
19. Avg. ml/week  Average quantity alcohol consumed per week (ml) 
20. Yrs. of alcohol  Number of years of alcohol intake 
21. Fish/week  Average quantity of fish intake per week (gm) 
22. Milk/day  Average quantity of dairy products intake per day (ml) 
23. Fortified  Whether milk is fortified? 
- 1 yes, 0 no 
24. Diabetic  Is the subject a known diabetic 
142 
 
- 1 yes, 0 no 
25. DM duration  Duration of diabetes in years 
26. DM treatment  Treatment for diabetes 
- 1 oral drugs, 2 only diet restriction, 3 
insulin 
27. Hypertension  Is the subject a known hypertensive 
- 1 yes, 0 no 
28. HT duration  Duration of hypertension (in years) 
29. Dyslipidemia  Is the subject a known case of dyslipidemia 
- 1 yes, 0 no 
30. Dys. Treatment Treatment for dyslipidemia 
- 1 Drugs, 2 Diet Control 
31. Weight  Weight (kg) 
32. Height   Height (cm) 
33. BMI    Body mass index 
34. SBP1   Systolic blood pressure 1 (mmHg) 
35. DBP1   Diastolic blood pressure 1 (mmHg) 
36. SBP2   Systolic blood pressure 2 (mmHg) 
37. SBP2   Diastolic blood pressure 2 (mmHg) 
38. Waist   Waist circumference (cm) 
39. AC   Fasting blood sugar (mg %) 
40. PC   Post prandial blood sugar (mg %) 
41. Cholesterol  Total Cholesterol (mg %) 
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42. Triglycerides  Triglycerides (mg %) 
43. HDL   High density lipoprotein (mg %) 
44. LDL   Low density lipoprotein (mg %) 
45. Vitamin D  Vitamin D level (ng/ml) 
46. Is control?  Is the subject recruited as control? 
- 1 yes, 0 no 
47. Derm. Diagnosis Dermatological diagnosis of controls 
1 Superficial fungal infection, 2 Viral wart, 3 STI 
screening, 4 Herpes labialis, 5 Molluscum contagiosum, 6 
Pityriasis capitis, 7 Fissures over heels, 8 Erythrasma, 9 
Cherry angioma, 10 Keloid, 11 Zoons balanitis, 12 Acne 
grade1, 13 Androgenetic alopecia, 14 Post herpetic 
neuralgia, 15 Post inflammatory hyperpigmentation, 16 
Black hairy tongue, 17 Pigmented purpuric dermatoses, 18 
Corn 
48. BSA %  Body surface area involved among controls (%) 
49. Onset age  Age at onset of psoriasis (years) 
50. Season   Seasonal exacerbation of psoriasis 
- 0 No seasonal change, 1 winter 
exacerbation, 2 summer exacerbation 
51. Avoidance  Does patient avoid social activities due to psoriasis 
- 1 yes, 0 no 
52. Reason  Reason for social avoidance 
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- 1 social reasons, 2 disability due to 
disease, 3 other reasons 
53. Topical Rx  Topical treatment for psoriasis 
- 1 Steroid, 2 Steroid + keratolytic, 3 
Keratolytics, 4 Retinoids, 5 tar, 6 Only 
emollients, 7 Alternative forms of 
medicine, 8 No treatment in the last 3 
months 
54. Nail invol.  Are there any psoriatic nail changes? 
- 1 yes, 0 no 
55. NAPSI   NAPSI Score 
56. Arthritis  Does the patient have arthritis? 
- 1 yes, 0 no 
57. CASPAR  CASPAR Score 
58. Moll Wright  Moll and Wright classification of arthritis 
- 1 Distal interphalangeal joints, 2 
Asymmetric oligoarthritis, 3 Symmetric 
polyarthritis, 4 Spondyloarthritis, 5 
Arthritis mutilans 
59. Symptomatic  Is arthritis symptomatic now 
- 1 yes, 0 no 
60. BSA invol.  Total BSA involvement among cases (%) 
61. PASI  Psoriasis area severity index score for cases 
